

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08460 A2

(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/GB01/03293

(22) International Filing Date: 20 July 2001 (20.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0018050.5 21 July 2000 (21.07.2000) GB

(71) Applicant (for all designated States except US):
NORCHIP A/S [NO/NO]; Industriveien 8, N-3490
Klokkarstua (NO).

(71) Applicant (for MG only): ALLARD, Susan, Joyce
[GB/GB]; Verulam Gardens, 70 Gray's Inn Road, London
WC1X 8BT (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): KARLSEN, Frank
[NO/NO]; Hovkastet 2, N-3490 Klokkarstua (NO).

(74) Agent: BOULT WADE TENNANT; Verulam Gardens,
70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designation US
- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/08460 A2

(54) Title: METHODS FOR DETECTION OF HUMAN PAPILLOMAVIRUS MRNA

(57) Abstract: Methods for detecting the presence of mRNA transcripts from the E6 or E7 genes of human papillomavirus in clinical samples using nucleic acid sequence-based amplification. Sets of degenerate oligonucleotide primers which may be used for simultaneous detection of multiple HPV types are also described.

- 1 -

METHODS FOR DETECTION OF HUMAN PAPILLOMAVIRUS mRNAField of the invention

The present invention is concerned with methods
5 of detecting the presence of human papillomavirus mRNA
in clinical samples using nucleic acid sequence-based
amplification and in particular with sets of
degenerate oligonucleotide primers for use in such
methods.

10

Background to the invention

Cervical cancer is closely associated with human
papillomavirus (HPV). More than 100 HPV genotypes have
been considered to date; types 16, 18, 31, 33, 35, 45,
15 52, 58 and 67 are considered to belong to the group
that puts patients infected with these types at high
risk for cervical carcinogenesis. Specific viral genes
(E6 and E7) from HPV types 16, 18 and 33 have been
proved to act as oncogenes. Their expression seems to
20 be necessary, but not sufficient, for conversion to
malignancy. Absence of HPV Type 16 E6 transcripts in
HPV 16 infected, cytological normal cervical scraping
prove that E6 and E7 markers may be used as prognostic
markers for screening of women at risk for the
25 development of cervical carcinoma (Falcinelli et al.,
J. Med. Virology., 1993). With in situ hybridisation
an increase in the expression of the viral early
region was observed with increasing cellular
differentiation and in high-grade lesions a uniform
30 distribution of high expression was observed (Durst et
al., Virology, 189:132-140., 1992). E7 protein is
multifunctional and enhances the degradation of
retinoblastoma gene products (Boyer et al., 1996) and
the E6 proteins accelerate in vitro degradation of P53
35 protein and effect the stability of p53 protein
intracellularly (Lechner et al., 1992). The E6 and E7
proteins are oncogenic, not only because of the

- 2 -

degradation of p53, RB and other tumour suppressor proteins, but also because of their influence on cell cycle control mediators p21, p27, E2F (transcription factor) and PCNA (proliferating cell nuclear antigen).
5 HPV types 16, 18 and 33 are often found integrated into chromosomes of cancerous cervical cells, and this integration has been postulated to result in increased levels of stabilities of gene E6 and E7 expression. Jeon and coworkers have also demonstrated that HPV
10 type 16 DNA integration correlates with increased levels of expression of the viral E7 protein and with a selective growth advantage over cells harbouring extrachromosomal HPV16 DNA. The existence of HPV-negative cervical cancers is now debatable; zur
15 Hausen and de Villiers have argued that if they do exist, their incidence should be low.

In the last few years, there has been an improvement in the methods used to detect HPV, with methods based on amplification of nucleic acids using
20 the polymerase chain reaction (PCR) becoming increasingly widespread. It is now possible to detect small amounts of HPV DNA (<100 pg), quantify the amount of viral DNA in clinical samples, identify a broad spectrum of genital HPV types, test for selected
25 HPV types and localise the viral genome transcripts and proteins to the individual cells. Since HPV detection is often carried out in the presence of vast quantities of host nucleic acids and cells not infected with the virus, the ability of the primers to
30 be virus specific is critical for a sensitive and specific amplification.

Concern has been expressed about the reproducibility of the PCR technique alone following reports of widely different estimates of the
35 prevalence of HPV 16 DNA sequences in normal and abnormal cervical epithelial (Franco et al., 1991). These problems of reproducibility have also been a

- 3 -

problem in squamous cell cervical carcinoma series where the detection rate of HPV 16 varied from 45 to 87%. This may be due to the sample preparation differences, inadequate primer construction and other methodological differences. However, one important factor is to include a probe related detection of the amplified product in order to increase the sensitivity.

10 NASBA (Nucleic acid sequence-based amplification) is a relatively new method for the amplification of RNA (Compton, Nature. 350: 91-92 (1991)). NASBA is well known by persons of ordinary skill in the art and is described, for example, in US-A-5,409,818. NASBA
15 is an effective procedure for generating large quantities of a target RNA sequence *in vitro*, allowing detection of target RNA sequences that are present in very low concentrations in the original test sample.

 The NASBA method is based on the same type of
20 primer-sets as for PCR but one primer is modified with a promotor sequence, for example a T7 promoter. The sensitivity and specificity of the NASBA amplification has been shown to be the same as for PCR and better than most RT-PCR protocols. Since the NASBA method is
25 an isothermal assay and it is dependent on RNase H it cannot amplify DNA. This is important in connection with detection of mRNA expression from the HPV genome where the RT-PCR method would amplify both the RNA and DNA. There is extensive literature on the use of
30 NASBA for the detection of HIV-1 in clinical samples (see for example Kievits et al., Journal of Virological Methods. 35: 273-286 (1991)).

 The present inventors have now applied the NASBA
35 technique to the detection of human papillomavirus (HPV) in test samples. The inventors' approach is based upon the development of degenerate primer

- 4 -

cocktails which allow simultaneous detection of two or more HPV types.

Description of the invention

5 In a first aspect the invention provides oligonucleotides, more particularly degenerate oligonucleotides, which may be used for the detection of specific combinations of HPV types.

10 In a first embodiment the invention provides an oligonucleotide for use in detecting the presence of human papilloma virus type 16, type 31, type 35 or a combination thereof in a test sample, said oligonucleotide being selected from the group
15 consisting of:

oligonucleotides comprising one of the following nucleotide sequences:

20 Primer 1 oligonucleotides:
5' X₁-AGRTCAGTTGYCTCDGGT [SEQ ID NO:1]
5' X₁-TCYGGTTYTGCTTGTTCCA [SEQ ID NO:2]
5' X₁-TGTGTGCTYTGACRCACAR [SEQ ID NO:3]
wherein X₁ represents a nucleotide sequence comprising
25 a promoter,

Primer 2 oligonucleotides:
5' CCRYTGTGTCCWGWGAA [SEQ ID NO:4]
5' TGCRTGGAGAWAYAMCTA [SEQ ID NO:5]
30 5' TATRTKTTAGATTTGSAACC [SEQ ID NO:6]

Probe oligonucleotides:
5' TGTAAWCATGCRTGGAGAWA [SEQ ID NO:7]
5' GAAACCSARSTGTAAWCATG [SEQ ID NO:8]
35 5' CATGCRTGGAGAWAYAMCTA [SEQ ID NO:9]
5' GACAGCTCAGAKGAGGAGGA [SEQ ID NO:10]
5' CAACTGAYCTMYACTGTTATGA [SEQ ID NO:11]

- 5 -

5' CAACTGAYCTMYACTGTTATGAGCAATT [SEQ ID NO:12]

and oligonucleotides comprising one of the following structures:

5

'Molecular beacon' probes:

5'X₂-CCGAGCACTGAYCTMYACTGTTATGAGCTCGG-X₃ [SEQ ID NO:13]

5'X₂-CCAAGCACTGAYCTMYACTGTTATGAGCTTGG-X₃ [SEQ ID NO:14]

5'X₂-CCAAGCCAACCTGAYCTMYACTGTTATGAGCAGCTTGG-X₃ [SEQ ID
10 NO:15]

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

15

In a second embodiment the invention provides an oligonucleotide for use in detecting the presence of human papilloma virus type 52, type 58, type 67 or a combination thereof in a test sample, said
20 oligonucleotide being selected from the group consisting of:

oligonucleotides comprising one of the following nucleotide sequences:

25

Primer 1 oligonucleotides:

5' X₁-TCCTCRTCCTGAGCTGTCA [SEQ ID NO:16]

5' X₁-TGCTTGTCCATCTGGCCGGT [SEQ ID NO:17]

wherein X₁ represents a nucleotide sequence comprising
30 a promoter,

Primer 2 oligonucleotides:

5' TGGACAGGRCGSTGTKCA [SEQ ID NO:18]

5' TGTKCAGWGTGTTGGAGA [SEQ ID NO:19]

35

Probe oligonucleotides:

5' CAACTGACCTAYWCTGCTATGA [SEQ ID NO:20]

- 6 -

5' GAAMCAACTGACCTAYWCTGCTAT [SEQ ID NO:21]

and oligonucleotides having one of the following structures:

5 'Molecular beacon' probes:

5' X₂-CCAAGCAANCAACTGACCTAYWCTGCTAGCTTGG-X₃ [SEQ ID NO:22]

5' X₂-CCAAGCACTGACCTAYWCTGCTATGAGCTTGG-X₃ [SEQ ID NO:23]

10 wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

15 In a third embodiment the invention provides an oligonucleotide for use in detecting the presence of human papilloma virus type 33, type 58 or a combination thereof in a test sample, said oligonucleotide being selected from the group
20 consisting of:

oligonucleotides comprising one of the following nucleotide sequences:

25 Primer 1 oligonucleotides:

5' X₁-CAAGTGTRACAACARGTTA [SEQ ID NO:24]

5' X₁-GCACAGSTAGGGCACACAA [SEQ ID NO:25]

wherein X₁ represents a nucleotide sequence comprising a promoter,

30

Primer 2 oligonucleotides:

5' CAACTGACCTATWCTGCTA [SEQ ID NO:26]

5' ATCCTGAACCAACTGACCTA [SEQ ID NO:27]

35 Probe oligonucleotides:

5'GTGACAGCTCAGAYGAGGATGA [SEQ ID NO:28]

5'GGCCAGATGGACAAGCACAAC [SEQ ID NO:29]

- 7 -

and oligonucleotides comprising one of the following structures:

'Molecular beacon' probes:

- 5 5' X₂-CCAAGCGCCAGATGGACAAGCACAAAGCTTGG-X₃ [SEQ ID NO:30]
5' X₂-CCGAGCGCCAGATGGACAAGCACAAAGCTCGG-X₃ [SEQ ID NO:31]
wherein X₂ and X₃ represent a fluorescent moiety and a
quencher moiety capable of substantially or completely
quenching the fluorescence from the fluorescent moiety
10 when the two are held together in close proximity.

- In a fourth embodiment the invention provides an
oligonucleotide for use in detecting the presence of
human papilloma virus type 18, type 45 or a
15 combination thereof in a test sample, said
oligonucleotide being selected from the group
consisting of:

- oligonucleotides comprising one of the following
20 nucleotide sequences:

Primer 1 oligonucleotides:

- 5' X₁-AGCTCAATTCTGSCKTCA [SEQ ID NO:32]
5' X₁-ACGGACACACAAAGGACA [SEQ ID NO:33]
25 5' X₁-GCACACCACGGACACACA [SEQ ID NO:34]
wherein X₁ represents a nucleotide sequence comprising
a promoter,

Primer 2 oligonucleotides:

- 30 5' ACGAGCAATTAAGCGAST [SEQ ID NO:35]
5' CCGACGAGCCGAACCACA [SEQ ID NO:36]

Probe oligonucleotides:

- 5'AGCCCGACGAGCCGAACCACA [SEQ ID NO:37]
35 5'GTTGTAAGTGTGAMGSCAGAATT [SEQ ID NO:38]

and oligonucleotides having the following structure:

5' X₂-CCAAGCAGCCCGACGAGCCGAACCACAGCTTGG-X₃ [SEQ ID NO:39]

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

The oligonucleotide molecules of the invention are preferably single stranded DNA molecules. Non-natural synthetic polynucleotides which retain the ability to base-pair with a complementary nucleic acid molecule and are able to function in the NASBA reaction are also within the scope of the invention, including synthetic oligonucleotides which incorporate modified bases and synthetic oligonucleotides wherein the links between individual nucleosides include bonds other than phosphodiester bonds. The oligonucleotide molecules of the invention may be produced according to techniques well known in the art, such as by chemical synthesis using standard apparatus and protocols for oligonucleotide synthesis. Representations of the sequences of degenerate oligonucleotide molecules provided herein use the standard IUB code for mixed base sites:

N=G,A,T,C; V=G,A,C; B=G,T,C; H=A,T,C; D=G,A,T; K=G,T; S=G,C; W=A,T; M=A,C; Y=C,T; R=A,G.

The oligonucleotide molecules of the invention are selected to be specific for mRNA transcribed from the HPV E6 or E7 genes, expression of which is associated with cervical cytological abnormalities which often progress to more serious disease. A number of studies relate the expression of the E6 and E7 genes to oncogenesis. Co-operation between E6 and E7 increases significantly the frequency of immortalization. Evidence has been presented that the

- 9 -

E6 and E7 open reading frames are involved in the transforming activity of the virus (Tanaka et al., J. Virol. 63: 1465-1469, 1989). These transformation effects of E6 and E7 may at least in part be explained by their interaction with the cellular tumour suppressor gene products p53 and pRb 105, respectively (Boyer et al., Cancer Research. 56: 4620-4624, 1996; Lechner et al. EMBO J. 11: 3045-3051, 1992). There is an extraordinary conservation of the E6 and E7 DNA and RNA sequence (Cone et al. J Med Virol. 37: 99-107. 1992). A number of publications have reported that E6 and E7 sequences are specific for each subtype of HPV (Karlsen et al., Eur J Cancer. 31A: 1511-1516, 1995; Karlsen et al., J Clin Microbiol. 34: 2095-2100, 1996).

The oligonucleotide molecules provided by the invention fall into four groups. Primer 1 (P1) oligonucleotide molecules are generally approximately 50 bases in length, with an average of about 20 bases at the 3' end that are complementary to a region of the target HPV mRNA. One or more of the bases in the 3' end region are degenerate, and this degeneracy results in specificity for two or more HPV types. The 5' ends of the primer 1 oligonucleotides (represented herein in general terms as X₁) comprise a promoter sequence that is recognized by a specific RNA polymerase. Bacteriophage promoters, for example the T7, T3 and SP6 promoters, are preferred for use in the oligonucleotides of the invention, since they provide advantages of high level transcription which is dependent only on binding of the appropriate RNA polymerase. In a preferred embodiment, the 5' terminal sequence of the primer 1 oligonucleotides may comprise the sequence AATTCTAATACGACTCACTATAGGG [SEQ ID NO:40] or the sequence AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62]. These

- 10 -

sequences contain a T7 promoter, including the transcription initiation site for T7 RNA polymerase.

The primer 2 (P2) oligonucleotides generally comprise a sequence of approximately 20 bases substantially identical to a region of the target HPV mRNA. As with the primer 1 oligonucleotides one or more of the bases in this sequence are degenerate, resulting in specificity for two or more HPV types. The primer 2 oligonucleotides may, in a particular but non-limiting embodiment, further comprise a sequence of nucleotides at the 5' end which is unrelated to HPV but which is capable of hybridising to a generic detection probe. The detection probe will preferably be labelled, for example with a fluorescent, luminescent or enzymatic label. In one embodiment the detection probe is labelled with a label that permits detection using ECL™ technology, although it will be appreciated that the invention is in no way limited to this particular method of detection. In a preferred embodiment the 5' end of the primer 2 oligonucleotides may comprise the sequence GATGCAAGGTCGCATATGAG [SEQ ID NO:41]. This sequence is capable of hybridising to a generic ECL™ probe commercially available from Organon Teknika having the following structure:

Ru(bpy)₃²⁺-GAT GCA AGG TCG CAT ATG AG-3'

In a different embodiment the primer 2 oligonucleotide may incorporate 'molecular beacons' technology, which is known in the art and described, for example, in WO 95/13399 by Tyagi and Kramer, Nature Biotechnology. 14: 303-308, 1996, to allow for real-time monitoring of the NASBA reaction.

The third type of oligonucleotide molecules provided by the invention are HPV-specific probe oligonucleotides. The probe oligonucleotides generally comprise a sequence of approximately 20-25

- 11 -

bases substantially identical to a region of the target HPV mRNA. One or more of the bases in this sequence may be degenerate, resulting in a probe mix which has specificity for two or more HPV types. The probe oligonucleotides may be used as HPV-specific hybridisation probes for detection of the products of a NASBA reaction. In this connection the probe oligonucleotides may be coupled to a solid support, such as paramagnetic beads, to form a capture probe (see below). In a preferred embodiment the 5' end of the probe oligonucleotide may be labelled with biotin. The addition of a biotin label facilitates attachment of the probe to a solid support via a biotin/streptavidin or biotin/avidin linkage.

The fourth type of oligonucleotide molecules provided by the invention are HPV-specific probes incorporating 'molecular beacons' technology which is known in the art and described, for example, by Tyagi and Kramer, Nature Biotechnology. 14: 303-308, 1996 and in WO 95/13399. The use of molecular beacons technology allows for real-time monitoring of the NASBA reaction. The molecular beacons primers generally include, in addition to a HPV-specific sequence including one or more degenerate bases, additional bases which allow formation of a hairpin loop structure, a fluorescent moiety and a quencher moiety, the fluorescent and the quencher moieties being represented herein by the notation X_2 and X_3 . As will be appreciated by the skilled reader, the fluorescer and quencher moieties are selected such that the quencher moiety is capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two moieties are in close proximity, e.g. when the probe is in the hairpin 'closed' conformation in the absence of the target sequence. Many examples of suitable pairs of quencher/fluorescer moieties which may be used in

- 12 -

accordance with the invention are known in the art (see WO 95/13399, Tyagi and Kramer, *ibid*). Preferred combinations include the fluorophore 5-(2'-aminoethyl)aminonaphthalene-1-sulphonic acid (EDANS) and the quencher 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL), although it will be appreciated that the invention is not limited to this particular combination. The fluorescer and quencher moieties may be covalently attached to the probe in either orientation, either with the fluorescer at or near the 5' end and the quencher at or near the 3' end or vice versa.

The oligonucleotide molecules of the invention may be used in the detection of HPV mRNA by NASBA. In particular, suitable combinations of primer 1 and primer 2 oligonucleotide molecules may be used to drive a NASBA amplification reaction. In order to drive a NASBA amplification reaction the primer 1 and primer 2 oligonucleotides must be capable of priming synthesis of a double-stranded DNA from a target region of mRNA, specifically HPV E6-E7 mRNA. For this to occur the primer 1 and primer 2 oligonucleotides must comprise HPV-specific sequences which are complementary to regions of the sense and the antisense strand of the target mRNA, respectively.

In the first phase of the NASBA amplification cycle, the so-called 'non-cyclic' phase, the primer 1 oligonucleotide anneals to a complementary sequence in the target mRNA and its 3' end is extended by the action of an RNA-dependent DNA polymerase (e.g. reverse transcriptase) to form a first-strand cDNA synthesis. The RNA strand of the resulting RNA:DNA hybrid is then digested, e.g. by the action of RnaseH, to leave a single stranded DNA. The primer 2 oligonucleotide anneals to a complementary sequence towards the 3' end of this single stranded DNA and its

- 13 -

3' end is extended (by the action of reverse transcriptase), forming a double stranded DNA. RNA polymerase is then able to transcribe multiple RNA copies from the now transcriptionally active promoter sequence within the double-stranded DNA. This RNA transcript, which is antisense to the original target mRNA, can act as a template for a further round of NASBA reactions, with primer 2 annealing to the RNA and priming synthesis of the first cDNA strand and primer 1 priming synthesis of the second cDNA strand. The general principles of the NASBA reaction are well known in the art (see Compton, J. Nature. 350: 91-92).

The HPV-specific probe oligonucleotides described herein may also be attached to a solid support, such as magnetic microbeads, and used as 'capture probes' to immobilise the product of the NASBA amplification reaction (a single stranded RNA). The HPV-specific 'molecular beacons' probes described herein may be used for real-time monitoring of the NASBA reaction (see Leone et al., Nucleic Acids Research., 1998, vol: 26, pp 2150-2155).

A list of specific oligonucleotide primers and probes provided by the invention is given below. However, it is not intended that this list should in any way be interpreted as limiting the scope of the invention to these specific molecules:

Oligonucleotides for the detection of HPV 16, 31, 35:

Primer 1 oligonucleotides

HPV AP2-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGA GRTCAGTTGYCTCDGGT [SEQ ID NO:42]
HPV AP1-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGT CYGGTTYTGCTTGTCCA [SEQ ID NO:43]
HPV AP3-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGT GTGTGCTYTGACRCACAR [SEQ ID NO:44]

- 14 -

Primer 2 oligonucleotides:

HPV AP2-2 5'GATGCAAGGTCGCATATGAGCCRYTGTGTCCW
GWWGAA [SEQ ID NO:45]
HPV AP1-2 5'GATGCAAGGTCGCATATGAGTGCRITGGAGAWA
YAMCTA [SEQ ID NO:46]
HPV AP3-2 5'GATGCAAGGTCGCATATGAGTATRTKTTAGAT
TTGSAACC [SEQ ID NO:47]

Probe oligonucleotides:

HPV APO2A 5'TGTAAWCATGCRITGGAGAWA [SEQ ID NO:7]
HPV APO2B 5'GAAACCSARSTGTAAWCATG [SEQ ID NO:8]
HPV APO2 5'CATGCRITGGAGAWAYAMCTA [SEQ ID NO:9]
HPV APO1 5'GACAGCTCAGAKGAGGAGGA [SEQ ID NO:10]
HPV APO1A 5'CAACTGAYCTMYACTGTTATGA [SEQ ID NO:11]
HPV APO1B 5'CAACTGAYCTMYACTGTTATGAGCAATT [SEQ ID
NO:12]

Oligonucleotides for the detection of HPV 52, 58, 67:

Primer 1 oligonucleotides:

HPV BP2-1 5'AATTCTAATACGACTCACTATAGGGAGAAGGT
CCTCRTCTGAGCTGTCA [SEQ ID NO:48]
HPV BP2A-1 5'AATTCTAATACGACTCACTATAGGGAGAAGGT
GCTTGTCCATCTGGCCGGT [SEQ ID NO:49]

Primer 2 oligonucleotides

HPV BP2-2 5'GATGCAAGGTCGCATATGAGTGGACAGGRCS
TGTKCA [SEQ ID NO:50]
HPV BP2A-2 5'GATGCAAGGTCGCATATGAGTGTCKAGWGTGT
TGGAGA [SEQ ID NO:51]

Probe oligonucleotides:

HPV BPO2 5'CAACTGACCTAYWCTGCTATGA [SEQ ID NO:20]
HPV BPO2A 5'GAAMCAACTGACCTAYWCTGCTAT [SEQ ID
NO:21]

Oligonucleotides for the detection of HPV 33, 58:

- 15 -

Primer 1 oligonucleotides:

HPV BP1-1 5'AATTCTAATACGACTCACTATAGGGAGAAGGC
AAGTGTRACAACARGTTA [SEQ ID NO:52]
HPV BP1A-1 5'AATTCTAATACGACTCACTATAGGGAGAAGGG
CACAGSTAGGGCACACAA [SEQ ID NO:53]

Primer 2 oligonucleotides:

HPV BP1-2 5'GATGCAAGGTCGCATATGAGCAACTGACCTAT
WCTGCTA [SEQ ID NO:54]
10 HPV BP1A-2 5'GATGCAAGGTCGCATATGAGATCCTGAACCAA
CTGACCTA [SEQ ID NO:55]

Probe oligonucleotides:

HPV BPO1 5'GTGACAGCTCAGAYGAGGATGA [SEQ ID NO:28]
15 HPV BPO1A 5'GGCCAGATGGACAAGCACAAAC [SEQ ID NO:29]

Oligonucleotides for the detection of HPV 18,45:

Primer 1 oligonucleotides:

HPVCP1-1 5'AATTCTAATACGACTCACTATAGGGAGAAGGA
20 GCTCAATTCTGSKTCA [SEQ ID NO:56]
HPVCP2-1 5'AATTCTAATACGACTCACTATAGGGAGAAGGA
CGGACACACAAAGGACA [SEQ ID NO:57]
HPVCP3-1 5'AATTCTAATACGACTCACTATAGGGAGAAGGG
CACACCACGGACACACA [SEQ ID NO:58]

25

Primer 2 oligonucleotides:

HPVCP1-2 5'GATGCAAGGTCGCATATGAGACGAGCAATTAA
GCGAST [SEQ ID NO:59]
HPVCP2-2 5'GATGCAAGGTCGCATATGAGACGAGCAATTAA
30 GCGAST [SEQ ID NO:60]
HPVCP3-2 5'GATGCAAGGTCGCATATGAGCCGACGAGCCGA
ACCACA [SEQ ID NO:61]

Probe oligonucleotides:

35 HPVCP01 5'AGCCCGACGAGCCGAACCACA [SEQ ID NO:37]
HPVCP03 5'GTTGTAAGTGTGAMGSCAGAATT [SEQ ID
NO:38]

- 16 -

Cocktails of primer-sets and probes comprising certain combinations of the oligonucleotide molecules of the invention are also the subject of the present invention, these primer cocktails being useful for the
 5 detection of various combinations of two or more HPV types by NASBA.

Therefore, in a particular embodiment the invention provides a first primer cocktail which is suitable for use in detecting the presence of human
 10 papilloma virus type 16, type 31, type 35 or a combination thereof in a test sample, the primer cocktail comprising a combination of oligonucleotide molecules having the following nucleotide sequences:

15 5' CCRYTGTGTCCGWWGAA [SEQ ID NO:4]
 5' TGCRTGGAGAWAYAMCTA [SEQ ID NO:5]
 5' TATRTKTTAGATTGSAACC [SEQ ID NO:6]
 5' X₁-AGRTCAGTTGYCTCDGGT [SEQ ID NO:1]
 5' X₁-TCYGGTTYTGCTTGTTCCA [SEQ ID NO:2]
 20 5' X₁-TGTGTGCTYTGTACRCACAR [SEQ ID NO:3]
 wherein X₁ represents a nucleotide sequence comprising a promoter,

In a preferred embodiment this first primer
 25 cocktail comprises the following combination of oligonucleotide molecules:

	<u>Primer name</u>	<u>Sequence</u>
	HPV AP2-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGA
30		GRTCAGTTGYCTCDGGT [SEQ ID NO:42]
	HPV AP2-2	5'GATGCAAGGTCGCATATGAGCCRYTGTGTCCW
		WWGAA [SEQ ID NO:45]
	HPV AP1-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGT
		CYGGTTYTGCTTGTTCCA [SEQ ID NO:43]
35	HPV AP1-2	5'GATGCAAGGTCGCATATGAGTGCRTGGAGAWA
		YAMCTA [SEQ ID NO:46]
	HPV AP3-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGT

- 17 -

HPV AP3-2 GTGTGCTYTGACRCACAR [SEQ ID NO:44]
5'GATGCAAGGTCGCATATGAGTATRTKTTAGAT
TTGSAACC [SEQ ID NO:47]

5 In a further embodiment the invention also provides a primer cocktail/probe mixture comprising the first primer cocktail according to the invention and a mixture of probe oligonucleotide molecules having the following nucleotide sequences:

10

5' TGTAAWCATGCRTGGAGAWA [SEQ ID NO:7]
5' GAAACCSARSTGTAAWCATG [SEQ ID NO:8]
5' CATGCRTGGAGAWAYAMCTA [SEQ ID NO:9]
5' GACAGCTCAGAKGAGGAGGA [SEQ ID NO:10]
15 5' CAACTGAYCTMYACTGTTATGA [SEQ ID NO:11]
5' CAACTGAYCTMYACTGTTATGAGCAATT [SEQ ID NO:12]

The invention still further provides a primer cocktail/probe mixture comprising the first primer cocktail according to the invention and a mixture of molecular beacon probe oligonucleotides having the following structures:

5' X₂-CCGAGCACTGAYCTMYACTGTTATGAGCTCGG-X₃ [SEQ ID
25 NO:13]
5' X₂-CCAAGCACTGAYCTMYACTGTTATGAGCTTGG-X₃ [SEQ ID
NO:14]
5' X₂-CCAAGCCAACTGAYCTMYACTGTTATGAGCAGCTTGG-X₃ [SEQ ID
NO:15]

30 wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

35 The invention also provides a second primer cocktail which is suitable for use in detecting the presence of human papilloma virus type 52, type 58,

- 18 -

type 67 or a combination thereof in a test sample, the primer cocktail comprising the following combination of oligonucleotide molecules:

5 5' TGGACAGGRCGSTGTKCA [SEQ ID NO:18]
 5' TGTKCAGWGTGTTGGAGA [SEQ ID NO:19]
 5' X₁-TCCTCRTCTGAGCTGTCA [SEQ ID NO:16]
 5' X₁-TGCTTGTCCTCATCTGGCCGGT [SEQ ID NO:17]
 wherein X₁ represents a nucleotide sequence comprising
 10 a promoter,

In a preferred embodiment the second primer cocktail may comprise the following combination of oligonucleotide molecules:

<u>Primer name</u>	<u>Sequence</u>
HPV BP2-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGT CCTCRTCTGAGCTGTCA [SEQ ID NO:48]
HPV BP2-2	5'GATGCAAGGTCGCATATGAGTGGACAGGRCGS TGTKCA [SEQ ID NO:50]
HPV BP2A-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGT GCTTGTCCTCATCTGGCCGGT [SEQ ID NO:49]
HPV BP2A-2	5'GATGCAAGGTCGCATATGAGTGTKCAGWGTGT TGGAGA [SEQ ID NO:51]

25 In a further embodiment the invention also provides a primer cocktail/probe mixture comprising a second primer cocktail according to the invention and a mixture of probe oligonucleotide molecules having
 30 the following sequences:

5' CAACTGACCTAYWCTGCTATGA [SEQ ID NO:20]
 5' GAAMCAACTGACCTAYWCTGCTAT [SEQ ID NO:21]

35 The invention further provides a primer cocktail/probe mixture comprising a second primer cocktail according to the invention and a mixture of

- 19 -

molecular beacon probe oligonucleotides having the following structures:

5' X₂-CCAAGCAANCAACTGACCTAYWCTGCTAGCTTGG-X₃ [SEQ ID NO:22]

5' X₂-CCAAGCACTGACCTAYWCTGCTATGAGCTTGG-X₃ [SEQ ID NO:23]

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

The invention also provides a third primer cocktail for use in detecting the presence of human papilloma virus type 33, type 58 or a combination thereof in a test sample, the primer cocktail comprising the following combination of oligonucleotides:

5' CAACTGACCTATWCTGCTA [SEQ ID NO:26]

5' ATCCTGAACCAACTGACCTA [SEQ ID NO:27]

5' X₁-CAAGTGTRACAACARGTTA [SEQ ID NO:24]

5' X₁-GCACAGSTAGGGCACACAA [SEQ ID NO:25]

wherein X₁ represents a nucleotide sequence comprising a promoter,

In a preferred embodiment the third primer cocktail may comprise the following combination of oligonucleotide molecules:

30

<u>Primer name</u>	<u>Sequence</u>
HPV BP1-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGC AAGTGTRACAACARGTTA [SEQ ID NO:52]
HPV BP1-2	5'GATGCAAGGTCGCATATGAGCAACTGACCTAT WCTGCTA [SEQ ID NO:54]
HPV BP1A-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGG CACAGSTAGGGCACACAA [SEQ ID NO:53]

35

- 20 -

HPV BP1A-2

5'GATGCAAGGTCGCATATGAGATCCTGAACCAA
CTGACCTA [SEQ ID NO:55]

In a further embodiment the invention also
5 provides a primer cocktail/probe mixture comprising a
third primer cocktail according to the invention and a
mixture of probe oligonucleotide molecules having the
following sequences:

10 5' GTGACAGCTCAGAYGAGGATGA [SEQ ID NO:28]
5' GGCCAGATGGACAAGCACAAC [SEQ ID NO:29]

The invention also provides a primer
cocktail/probe mixture comprising a third primer
15 cocktail according to the invention and a mixture of
molecular beacon probe oligonucleotide molecules
having the following structures:

5' X₂-CCAAGCGCCAGATGGACAAGCACAAGCTTGG-X₃ [SEQ ID NO:30]
20 5' X₂-CCGAGCGCCAGATGGACAAGCACAAGCTCGG-X₃ [SEQ ID NO:31]
wherein X₂ and X₃ represent a fluorescent moiety and a
quencher moiety capable of substantially or completely
quenching the fluorescence from the fluorescent moiety
when the two are held together in close proximity.

25
The invention still further provides a fourth
primer cocktail for use in detecting the presence of
human papilloma virus type 18, type 45 or a
combination thereof in a test sample, the primer
30 cocktail comprising the following combination of
oligonucleotides:

5' ACGAGCAATTAAGCGAST [SEQ ID NO:35]
5' CCGACGAGCCGAACCACA [SEQ ID NO:36]
35 5' X₁-AGCTCAATTCTGSKTCA [SEQ ID NO:32]
5' X₁-ACGGACACACAAAGGACA [SEQ ID NO:33]
5' X₁-GCACACCACGGACACACA [SEQ ID NO:34]

- 21 -

wherein X_1 represents a nucleotide sequence comprising a promoter,

5 In a preferred embodiment the fourth primer cocktail may comprise the following combination of oligonucleotide molecules:

	<u>Primer name</u>	<u>Sequence</u>
10	HPVCP1-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGA GCTCAATTCTGSCKTCA [SEQ ID NO:56]
	HPVCP1-2	5'GATGCAAGGTTCGCATATGAGACGAGCAATTAA GCGAST [SEQ ID NO:59]
	HPVCP2-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGA CGGACACACAAAGGACA [SEQ ID NO:57]
15	HPVCP2-2	5'GATGCAAGGTTCGCATATGAGACGAGCAATTAA GCGAST [SEQ ID NO:60]
	HPVCP3-1	5'AATTCTAATACGACTCACTATAGGGAGAAGGG CACACCACGGACACACA [SEQ ID NO:58]
20	HPVCP3-2	5'GATGCAAGGTTCGCATATGAGCCGACGAGCCGA ACCACA [SEQ ID NO:61]

25 In a further embodiment the invention provides a primer cocktail/probe mixture comprising a fourth primer cocktail according to the invention and a mixture of probe oligonucleotide molecules having the following sequences:

30 5' AGCCCGACGAGCCGAACCACA [SEQ ID NO:37]
5' GTTGTAAGTGTGAMGSCAGAATT [SEQ ID NO:38]

The invention also provides a primer cocktail/probe mixture comprising a fourth primer cocktail according to the invention and a molecular beacon probe oligonucleotide molecule having the following structure:

35

5' X_2 -CCAAGCAGCCCGACGAGCCGAACCACAGCTTGG- X_3 [SEQ ID

- 22 -

NO:39]

wherein X_2 and X_3 represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

The primer cocktails provided by the invention are mixtures of degenerate primer 1 and primer 2 oligonucleotides which collectively have specificity for two or more defined HPV types. The primer cocktails may be used to amplify HPV mRNA in a test sample by nucleic acid sequence-based amplification under standard NASBA conditions which are well known in the art. The primer cocktail/probe mixtures additionally contain degenerate probe oligonucleotides having specificity for the same HPV types. The mixtures of primer cocktails and molecular beacon probes may be used to detect HPV mRNA by real-time NASBA.

The primer cocktails and primer cocktail/probe mixtures may be supplied in the form of a solution in an appropriate buffer or they may be supplied in lyophilised or dried form and then reconstituted prior to use by the addition of a suitable buffer. Advantageously, they may be included in kits of reagents for HPV detection, as described below.

The primer cocktails of the invention allow simultaneous detection of combinations of two or more HPV types in a single NASBA reaction. The inventors' proposal of different cocktails of degenerate primer-sets that may be used to amplify transcripts from the E6 and E7 oncogenes, and in particular the ability to simultaneously detect several HPV types, represents a novel approach to the problem of detecting HPV transcripts that provides certain advantages over the prior art methods of HPV

- 23 -

detection, both in terms sensitivity and specificity and automation of large scale screening/detection programs.

5 A novel aspect of the inventors' approach is the simultaneous detection of combinations of HPV types. The combination is possible due to the similarity of the different HPV types. It is possible to construct NASBA primers against all the different oncogene types of HPV. However, a system that includes 13 different
10 marker units is very difficult to automate on a large scale. With the use of the degenerate primer cocktails provided by the invention it is possible to screen for HPV types 16, 31, 35, 52, 58, 67, 33, 18 and 45 simultaneously using only 4 different marker
15 units. This system is much more useful for robotic based diagnostics on a large number of patient samples.

In addition to the primer cocktails described
20 above the invention further provides individual primer sets, i.e. pairs of primer 1 and primer 2 oligonucleotides, and also primer set/probe mixtures all of which may be used for the detection of HPV by NASBA.

25 Therefore, in a further aspect the invention provides three different oligonucleotide primer sets for use in the detection of HPV type 16, type 31, type 35 or a combination thereof in a test sample, as follows:

30 Primer set 1 comprising a first oligonucleotide primer comprising the sequence 5' X₁-AGRTCAGTTGYCTCDGGT [SEQ ID NO:1], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide
35 primer comprising the sequence 5' CCRYTGTGTCCGWWGAA [SEQ ID NO:4].

- 24 -

Primer set 2 comprising a first oligonucleotide primer comprising the sequence 5' X₁-TCYGGTTYTGCTTGCCA [SEQ ID NO:2], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' TGCRTGGAGAWAYAMCTA [SEQ ID NO:5].

Primer set 3 comprising a first oligonucleotide primer comprising the sequence 5' X₁-TGTGTGCTYTGTACRCACAR [SEQ ID NO:3], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' TATRTKTTAGATTGSAACC [SEQ ID NO:6].

In each case X₁ preferably represents a nucleotide sequence comprising a T7 promoter, and even more preferably represents the nucleotide sequence AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

The invention still further provides two different probe/primer mixtures for use in the detection of HPV type 16, type 31, type 35 or a combination thereof in a test sample, as follows:

Probe primer mixture 1 comprising oligonucleotide primer set 1 as defined above and at least one oligonucleotide probe comprising a nucleotide sequence selected from the group consisting of:

5' TGTAAWCATGCRTGGAGAWA [SEQ ID NO:7]
5' GAAACCSARSTGTAAWCATG [SEQ ID NO:8]
5' CATGCRTGGAGAWAYAMCTA [SEQ ID NO:9]

Probe/primer mixture 2 comprising oligonucleotide primer set 2 or 3, as defined above and at least one oligonucleotide probe selected from the group consisting of:

- 25 -

oligonucleotide probes comprising one of the following nucleotide sequences:

- 5' GACAGCTCAGAKGAGGAGGA [SEQ ID NO:10]
5 5' CAACTGAYCTMYACTGTTATGA [SEQ ID NO:11]
5' CAACTGAYCTMYACTGTTATGAGCAATT [SEQ ID NO:12]

and oligonucleotide probes having one of the following structures:

- 10 5' X₂-CCGAGCACTGAYCTMYACTGTTATGAGCTCGG-X₃ [SEQ ID NO:13]
5' X₂-CCAAGCACTGAYCTMYACTGTTATGAGCTTGG-X₃ [SEQ ID NO:14]
15 5' X₂-CCAAGCCAAGCTGAYCTMYACTGTTATGAGCAGCTTGG-X₃ [SEQ ID NO:15]

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

20

In a still further aspect the invention provides two different oligonucleotide primer sets for use in the detection of HPV type 52, type 58 or type 67 or a combination thereof in a test sample, as follows:

25

Primer set 4 comprising a first oligonucleotide primer comprising the sequence 5' X₁-TCCTCRTCTGAGCTGTCA [SEQ ID NO:16], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' TGGACAGGRCGSTGTC [SEQ ID NO:18].

30

Primer set 5 comprising a first oligonucleotide primer comprising the sequence 5' X₁-TGCTTGTCATCTGGCCGGT [SEQ ID NO:17], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second

35

- 26 -

oligonucleotide primer comprising the sequence 5'
TGTKCAGWGTGTTGGAGA [SEQ ID NO:19].

In each case X_1 preferably represents a
5 nucleotide sequence comprising a T7 promoter, and even
more preferably represents the nucleotide sequence
AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

The invention further provides a probe/primer
10 mixture for use in the detection of HPV type 52, type
58, type 67 or a combination thereof in a test sample,
as follows:

Probe/primer mixture 3 comprising oligonucleotide
15 primer set 4 or 5, as defined above, and at least one
oligonucleotide probe selected from the group
consisting of:

oligonucleotide probes comprising one of the following
20 nucleotide sequences:

5' CAACTGACCTAYWCTGCTATGA [SEQ ID NO:20]

5' GAAMCAACTGACCTAYWCTGCTAT [SEQ ID NO:21]

25 and oligonucleotide probes having one of the following
structures:

5' X_2 -CCAAGCAANCAACTGACCTAYWCTGCTAGCTTGG- X_3 [SEQ ID
NO:22]

30 5' X_2 -CCAAGCACTGACCTAYWCTGCTATGAGCTTGG- X_3 [SEQ ID
NO:23]

wherein X_2 and X_3 represent a fluorescent moiety and a
quencher moiety capable of substantially or completely
quenching the fluorescence from the fluorescent moiety
35 when the two are held together in close proximity.

In a still further aspect the invention provides

- 27 -

two oligonucleotide primer sets for use in the detection of HPV type 33, type 58 or a combination thereof in a test sample, as follows:

5 Primer set 6 comprising a first oligonucleotide primer comprising the sequence 5' X₁-CAAGTGTRACAACARGTTA [SEQ ID NO:24], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' CAACTGACCTATWCTGCTA
10 [SEQ ID NO:26].

Primer set 7 comprising a first oligonucleotide primer comprising the sequence 5' X₁-GCACAGSTAGGGCACACAA [SEQ ID NO:25], wherein X₁ represents a nucleotide sequence
15 comprising a promoter, and a second oligonucleotide primer comprising the sequence 5'ATCCTGAACCAACTGACCTA [SEQ ID NO:27].

In each case X₁ preferably represents a
20 nucleotide sequence comprising a T7 promoter, and even more preferably represents the nucleotide sequence AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

The invention further provides a probe/primer
25 mixture for use in the detection of HPV type 33, type 58 or a combination thereof in a test sample, as follows:

Probe/primer mixture 4 comprising oligonucleotide
30 primer set 6 or 7, as defined above, and at least one oligonucleotide probe selected from the group consisting of:

oligonucleotide probes comprising one of the following
35 nucleotide sequences:

5' GTGACAGCTCAGAYGAGGATGA [SEQ ID NO:28]

- 28 -

5' GGCCAGATGGACAAGCACAAC [SEQ ID NO:29]

and oligonucleotide probes having one of the following structures:

5

5' X₂-CCAAGCGCCAGATGGACAAGCACAAGCTTGG-X₃ [SEQ ID NO:30]

5' X₂-CCGAGCGCCAGATGGACAAGCACAAGCTCGG-X₃ [SEQ ID NO:31]

10

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

15

In a still further aspect the invention provides three different oligonucleotide primer sets for use in the detection of HPV type 45, type 18 or a combination thereof in a test sample, as follows:

20

Primer set 8 comprising a first oligonucleotide primer comprising the sequence 5' X₁-AGCTCAATTCTGSCKTCA [SEQ ID NO:32], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' ACGAGCAATTAAGCGAST [SEQ ID NO:35].

25

Primer set 9 comprising a first oligonucleotide primer comprising the sequence 5' X₁-ACGGACACACAAAGGACA [SEQ ID NO:33], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' ACGAGCAATTAAGCGAST [SEQ ID NO:35].

30

35

Primer set 10 comprising a first oligonucleotide primer comprising the sequence 5' X₁-GCACACCACGGACACACA [SEQ ID NO:34], wherein X₁ represents a nucleotide sequence comprising a

- 29 -

promoter, and a second oligonucleotide primer comprising the sequence 5' CCGACGAGCCGAACCACA [SEQ ID NO:36].

5 In each case X_1 preferably represents a nucleotide sequence comprising a T7 promoter, and even more preferably represents the nucleotide sequence AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

10 The invention still further provides two different probe/primer mixtures for use in the detection of HPV type 45, type 18 or a combination thereof in a test sample, as follows:

15 Probe/primer mixture 5 comprising oligonucleotide primer set 8, as defined above, and at least one of: an oligonucleotide probe comprising the nucleotide sequence 5' AGCCCGACGAGCCGAACCACA [SEQ ID NO:37] or an oligonucleotide probe having the structure
20 5' X_2 -CCAAGCAGCCCGACGAGCCGAACCACAGCTTGG- X_3 [SEQ ID NO:39] wherein X_2 and X_3 represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in
25 close proximity.

 Probe/primer mixture 6 comprising oligonucleotide primer set 9 or 10, as defined above, and at least one of: an oligonucleotide probe comprising the nucleotide
30 sequence 5' GTTGTAAGTGTGAMGSCAGAATT [SEQ ID NO:38] an oligonucleotide probe having the structure
 5' X_2 -CCAAGCAGCCCGACGAGCCGAACCACAGCTTGG- X_3 [SEQ ID NO:39] wherein X_2 and X_3 represent a fluorescent moiety and a quencher moiety capable of substantially or
35 completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

- 30 -

The primer sets and probe/primer mixtures may also be supplied in the form of a solution in an appropriate buffer or in a lyophilised or dried form which may be reconstituted prior to use by the
5 addition of a suitable buffer. Advantageously, they may be included in kits of reagents for HPV detection, as described below.

Also provided by the invention are reagent kits
10 for use in the detection of HPV by NASBA, the kits comprising one or more oligonucleotide primer cocktails or primer sets according to the invention. The reagent kits may further comprise a mixture of enzymes required for the NASBA reaction, specifically
15 an enzyme mixture containing an RNA directed DNA polymerase (e.g. a reverse transcriptase), a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without hydrolysing single or double stranded RNA or DNA (e.g. RNaseH) and an RNA
20 polymerase. The RNA polymerase should be one which recognises the promoter sequence present in the 5' terminal region of the primer 1 oligonucleotides in the oligonucleotide primer cocktails or primer sets supplied in the reagent kit. The kit may also
25 comprise a supply of NASBA buffer containing the ribonucleosides and deoxyribonucleosides required for RNA and DNA synthesis. Details of the composition of a standard NASBA reaction buffer are given in the accompanying examples.

30 In certain embodiments the kit may further contain one or more capture probes, comprising a probe oligonucleotide attached to a solid support as described above, for immobilising the products of a specific NASBA reaction. The kit may still further
35 contain labelled generic detection probes. Advantageously, the detection probes may comprise a sequence of nucleotides complementary to a non-HPV

- 31 -

sequence present at the 5' terminal end of the primer
2 oligonucleotides present in the reagent kit.

5 In still further embodiments the kit may further
contain one or more molecular beacon probes according
to the invention. The molecular beacon probes may be
supplied as a separate reagent within the kit or may
be supplied in a primer cocktail/probe or primer
set/probe mixture.

10 In a still further aspect the invention provides
methods for the detection of HPV in test samples using
the NASBA technique. These methods generally comprise
the following steps:

15 (a) providing a reaction medium comprising a
primer cocktail or a primer set according to the
invention, an RNA directed DNA polymerase, a
ribonuclease that hydrolyses the RNA strand of an RNA-
DNA hybrid without hydrolysing single or double
stranded RNA or DNA, an RNA polymerase that recognises
20 said promoter, and ribonucleoside and
deoxyribonucleoside triphosphates;

(b) incubating said reaction medium with a
preparation of nucleic acid isolated from a test
sample suspected of containing HPV under reaction
25 conditions which permit a NASBA amplification
reaction; and

(c) detecting and/or quantitatively measuring
any HPV-specific product of the NASBA amplification
reaction.

30

The 'test sample suspected of containing HPV'
will most commonly be a clinical sample, for example a
cervical scraping in the cervical screening field.

35 The NASBA reaction will preferably be carried out
on a preparation of nucleic acid isolated from the
test sample. This preparation of nucleic acid must
include mRNA, however it need not be a preparation of

- 32 -

purified poly A+ mRNA and preparations of total RNA or even preparations of total nucleic acid containing both RNA and genomic DNA are also suitable as starting material for a NASBA reaction. Essentially any
5 technique known in the art for the isolation of a preparation of nucleic acid including mRNA may be used to isolate nucleic acid from the test sample. A preferred technique is the "Boom" isolation method described in US-A-5,234,809 and EP-B-0389,063. This
10 method, which can be used to isolate a nucleic acid preparation containing both RNA and DNA, is based on the nucleic acid binding properties of silicon dioxide particles in the presence of the chaotropic agent guanidine thiocyanate (GuSCN).

15 Detection of the specific product(s) of the NASBA reaction (i.e. sense and/or antisense copies of the target RNA) may be carried out in a number of different ways. In one approach the NASBA product(s) may be detected with the use of an HPV-specific
20 hybridisation probe capable of specifically annealing to the NASBA product. The hybridisation probe may be attached to a revealing label, for example a fluorescent, luminescent, radioactive or chemiluminescent compound or an enzyme label or any
25 other type of label known to those of ordinary skill in the art. The precise nature of the label is not critical, but it should be capable of producing a signal detectable by external means, either by itself or in conjunction with one or more additional
30 substances (e.g. the substrate for an enzyme).

Also within the scope of the invention is so-called 'real-time NASBA' which allows continuous monitoring of the formation of the product of the NASBA reaction over the course of the reaction. This
35 may be achieved using a 'molecular beacons' probe comprising an HPV-specific sequence capable of annealing to the NASBA product, a hairpin forming

- 33 -

oligonucleotide sequence and a pair of
fluorescer/quencher moieties, as described in WO
95/13399. If the molecular beacons probe is added to
the reaction mixture prior to amplification it may be
5 possible to monitor the formation of the NASBA product
in real-time (see Leone et al., Nucleic Acids
Research., 1998, vol: 26, pp 2150-2155).

In a further approach, the molecular beacons
technology may be incorporated into the primer 2
10 oligonucleotide allowing real-time monitoring of the
NASBA reaction without the need for a separate
hybridisation probe.

In a still further approach the products of the
NASBA reaction may be monitored using a generic
15 labelled detection probe which hybridises to a
nucleotide sequence in the 5' terminus of primer 2.
This is equivalent to the 'NucliSens™' detection
system supplied by Organon Teknika. In this system
specificity for NASBA products derived from the target
20 HPV mRNA may be conferred by using HPV-specific
capture probes comprising probe oligonucleotides as
described herein attached to a solid support such as a
magnetic microbead. Most preferably the generic
labelled detection probe is the ECL™ detection probe
25 supplied by Organon Teknika. NASBA amplicons are
hybridized to the HPV-specific capture probes and the
generic ECL probe (via a complementary sequence on
primer 2). Following hybridization the
bead/amplicon/ECL probe complexes may be captured at
30 the magnet electrode of an automatic ECL reader (e.g.
the NucliSens™ reader supplied by Organon Teknika.
Subsequently, a voltage pulse triggers the ECL™
reaction.

The invention provides a number of HPV-specific
35 oligonucleotide probes, including molecular beacons
probes, and it will be readily apparent to one of
ordinary skill in the art from the foregoing

- 34 -

description which probes or mixtures of probes are suitable for use with a given primer cocktail or primer set.

- 5 The present invention will be further understood with reference to the following Examples:

Example 1-Design of NASBA primer cocktails

- 10 The degenerated primer sets were constructed as follows:

We used the newly released program (year 2000) included in the series of Blast programs to compare
15 all the different E6 and E7 genes from the 13 HPV types: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. From the raw data of the compared sequences we carefully performed a manual search for areas that fulfilled the following criteria in addition to the
20 similarity:

1. Reduced hairpin formation (less than 3 bases)
2. Reduced dimer formation (less than 3 bases)
3. Ideal internal stability
- 25 4. Primer length (without the attached T7 RNA polymerase promotor sequence) between 20 and 25.
5. Probe length between 20 and 25.
6. Length of the amplification product between 120 and 250.
- 30 7. Must have 1 or 2 A bases as the final nucleotide at the 3'-end
8. Must have G+C content of 40-60%
9. The first 10 nts following the promotor sequence of primer 1 must be purine rich.
- 35 10. No stretches of pyrimidines in the first 10-12 nucleotides.
11. No false priming either in the sense or in the

- 35 -

antisense of the targeted sequence.

12. The stability of the primer-set compared to the product has to be optimal.
13. The delta G value of the two different primer-set
5 has to be equal.
14. The T_m difference has to be under 4 to 5°C.
15. The annealing temperature must be below 55°C.
16. The number of mixed bases sites have to be under
4.

10

Example 2-Real-time NASBA

The final real-time NASBA reaction buffer consists of the following components:

- 15 NASBA buffer: 3 ng/nl molecular beacon probe, 1 mM of each dNTP, 2 mM of ATP, UTP and CTP, 1.5 mM GTP, and 0.5 mM ITP, 0.5 mM dithiotreitol, 70 mM KCl, 12 mM MgCl₂, 40 mM Tris-HCl (pH 8.5).

The primer mix solution consist of 45% DMSO and 0.2 µM each of the antisense and sense primers.

- 20 The enzyme mix consists of 375 mM sorbitol, 2.5 µg BSA, 0.08 U RNase H, 32 U T7 RNA polymerase and 6.4 U AMV-reverse transcriptase.

Claims:

1. An oligonucleotide molecule for use in determining the presence of human papilloma virus type
5 16, type 31, type 35 or a combination thereof in a test sample, said oligonucleotide being selected from any of groups (i) to (iv) consisting of:

10 (i) oligonucleotides comprising one of the following nucleotide sequences:

5' X₁-AGRTCAGTTGYCTCDGGT [SEQ ID NO:1]

5' X₁-TCYGGTTYTGCTTGTCCA [SEQ ID NO:2]

5' X₁-TGTGTGCTYTGTACRCACAR [SEQ ID NO:3]

15 wherein X₁ represents a nucleotide sequence comprising a promoter

(ii) oligonucleotides comprising one of the following nucleotide sequences:

20

5' CCRYTGTGTCCWGWGAA [SEQ ID NO:4]

5' TGCRTGGAGAWAYAMCTA [SEQ ID NO:5]

5' TATRTKTTAGATTGSAACC [SEQ ID NO:6]

25 (iii) oligonucleotides comprising one of the following nucleotide sequences:

5' TGTAAWCATGCRTGGAGAWA [SEQ ID NO:7]

5' GAAACCSARSTGTAAWCATG [SEQ ID NO:8]

30 5' CATGCRTGGAGAWAYAMCTA [SEQ ID NO:9]

5' GACAGCTCAGAKGAGGAGGA [SEQ ID NO:10]

5' CAACTGAYCTMYACTGTTATGA [SEQ ID NO:11]

5' CAACTGAYCTMYACTGTTATGAGCAATT [SEQ ID NO:12]

35 (iv) oligonucleotides comprising one of the following structures:

- 37 -

5' X₂-CCGAGCACTGAYCTMYACTGTTATGAGCTCGG-X₃ [SEQ ID
NO:13]

5' X₂-CCAAGCACTGAYCTMYACTGTTATGAGCTTGG-X₃ [SEQ ID
NO:14]

5 5' X₂-CCAAGCCAACCTGAYCTMYACTGTTATGAGCAGCTTGG-X₃ [SEQ ID
NO:15]

10 wherein X₂ and X₃ represent a fluorescent moiety and a
quencher moiety capable of substantially or completely
quenching the fluorescence from the fluorescent moiety
when the two are held together in close proximity.

2. An oligonucleotide molecule according to
claim 1 wherein X₁ represents a nucleotide sequence
15 comprising a T7 promoter.

3. An oligonucleotide molecule according to
claim 1 which comprises a sequence selected from the
group consisting of:

20

5' AATTCTAATACGACTCACTATAGGGAGAAGGAGRTCAGTTGYCTCDGGT
[SEQ ID NO:42]

5' GATGCAAGGTCGCATATGAGCCRYTGTGTCCWGWGAA [SEQ ID
NO:45]

25 5' AATTCTAATACGACTCACTATAGGGAGAAGGTCYGGTTYTGCTTGTCCA
[SEQ ID NO:43]

5' GATGCAAGGTCGCATATGAGTGCRITGGAGAWAYAMCTA [SEQ ID
NO:46]

5' AATTCTAATACGACTCACTATAGGGAGAAGGTGTGTGCTYTGTACRCACAR
30 [SEQ ID NO:44]

5' GATGCAAGGTCGCATATGAGTATRTKTTAGATTGSAACC [SEQ ID
NO:47]

4. An oligonucleotide molecule for use in
35 determining the presence of human papilloma virus type
52, type 58, type 67 or a combination thereof in a
test sample, said oligonucleotide being selected from

- 38 -

any of groups (i) to (iv) consisting of:

(i) oligonucleotides comprising one of the following nucleotide sequences:

5

5' X₁-TCCTCRTCCTGAGCTGTCA [SEQ ID NO:16]

5' X₁-TGCTTGTCCTATCTGGCCGGT [SEQ ID NO:17]

wherein X₁ represents a nucleotide sequence comprising a promoter,

10

(ii) oligonucleotides comprising one of the following nucleotide sequences:

5' TGGACAGGRCGSTGTKCA [SEQ ID NO:18]

15

5' TGTKCAGWGTGTTGGAGA [SEQ ID NO:19]

(iii) oligonucleotides comprising one of the following nucleotide sequences:

20

5' CAACTGACCTAYWCTGCTATGA [SEQ ID NO:20]

5' GAAMCAACTGACCTAYWCTGCTAT [SEQ ID NO:21]

(iv) oligonucleotides comprising one of the following structures:

25

5' X₂-CCAAGCAANCAACTGACCTAYWCTGCTAGCTTGG-X₃ [SEQ ID NO:22]

5' X₂-CCAAGCACTGACCTAYWCTGCTATGAGCTTGG-X₃ [SEQ ID NO:23]

30

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

35

5. An oligonucleotide molecule according to claim 4 wherein X₁ represents a nucleotide sequence comprising a T7 promoter.

- 39 -

6. An oligonucleotide molecule according to claim 4 which comprises a sequence selected from the group consisting of:

5 5' AATTCTAATACGACTCACTATAGGGAGAAGGTCCTCCTCTGAGCTGTCA
[SEQ ID NO:48]
5' GATGCAAGGTCGCATATGAGTGGACAGGRCGSTGTKCA [SEQ ID
NO:50]
5' AATTCTAATACGACTCACTATAGGGAGAAGGTGCTTGTCCATCTGGCCGGT
10 [SEQ ID NO:49]
5' GATGCAAGGTCGCATATGAGTGTKCAGWGTGTTGGAGA [SEQ ID
NO:50]

7. An oligonucleotide molecule for use in
15 determining the presence of human papilloma virus type
33, type 58 or a combination thereof in a test sample,
said oligonucleotide being selected from any of groups
(i) to (iv) consisting of:

20 (i) oligonucleotides comprising one of the following
nucleotide sequences:

5' X₁-CAAGTGTRACAACARGTTA [SEQ ID NO:24]
5' X₁-GCACAGSTAGGGCACACAA [SEQ ID NO:25]
25 wherein X₁ represents a nucleotide sequence comprising
a promoter,

(ii) oligonucleotides comprising one of the following
nucleotide sequences:

30 5' CAACTGACCTATWCTGCTA [SEQ ID NO:26]
5' ATCCTGAACCAACTGACCTA [SEQ ID NO:27]

(iii) oligonucleotides comprising one of the following
35 nucleotide sequences:

5'GTGACAGCTCAGAYGAGGATGA [SEQ ID NO:28]

- 40 -

5'GGCCAGATGGACAAGCACAAC [SEQ ID NO:29]

(iv) oligonucleotides comprising one of the following structures:

5

5' X₂-CCAAGCGCCAGATGGACAAGCACAAGCTTGG-X₃ [SEQ ID NO:30]

5' X₂-CCGAGCGCCAGATGGACAAGCACAAGCTCGG-X₃ [SEQ ID NO:31]

10

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

15

8. An oligonucleotide molecule according to claim 7 wherein X₁ represents a nucleotide sequence comprising a T7 promoter.

20

9. An oligonucleotide molecule according to claim 7 which comprises a sequence selected from the group consisting of:

5' AATTCTAATACGACTCACTATAGGGAGAAGGCAAGTGTRACAACARGTTA [SEQ ID NO:52]

25

5' GATGCAAGGTCGCATATGAGCAACTGACCTATWCTGCTA [SEQ ID NO:54]

5' AATTCTAATACGACTCACTATAGGGAGAAGGGCACAGSTAGGGCACACAA [SEQ ID NO:53]

5' GATGCAAGGTCGCATATGAGATCCTGAACCAACTGACCTA [SEQ ID NO:55]

30

10. An oligonucleotide molecule for use in determining the presence of human papilloma virus type 18, type 45 or a combination thereof in a test sample, said oligonucleotide being selected from any of groups

35

(i) to (iv) consisting of:

(i) oligonucleotides comprising one of the following

- 41 -

nucleotide sequences:

5' X₁-AGCTCAATTCTGSCKTCA [SEQ ID NO:32]

5' X₁-ACGGACACACAAAGGACA [SEQ ID NO:33]

5 5' X₁-GCACACCACGGACACACA [SEQ ID NO:34]

wherein X₁ represents a nucleotide sequence comprising a promoter,

10 (ii) oligonucleotides comprising one of the following nucleotide sequences:

5' ACGAGCAATTAAGCGAST [SEQ ID NO:35]

5' CCGACGAGCCGAACCACA [SEQ ID NO:36]

15 (iii) oligonucleotides comprising one of the following nucleotide sequences:

5'AGCCCGACGAGCCGAACCACA [SEQ ID NO:37]

5'GTTGTAAGTGTGAMGSCAGAATT [SEQ ID NO:38]

20

(iv) oligonucleotides having the following structure:

5' X₂-CCAAGCAGCCCGACGAGCCGAACCACAGCTTGG-X₃ [SEQ ID NO:39]

25 wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

30 11. An oligonucleotide molecule according to claim 10 wherein X₁ represents a nucleotide sequence comprising a T7 promoter.

35 12. An oligonucleotide molecule according to claim 10 which comprises a sequence selected from the group consisting of:

- 42 -

5' AATTCTAATACGACTCACTATAGGGAGAAGGAGCTCAATTCTGSCKTCA
[SEQ ID NO:56]

5' GATGCAAGGTCGCATATGAGACGAGCAATTAAGCGAST [SEQ ID
NO:59]

5 5' AATTCTAATACGACTCACTATAGGGAGAAGGACGGACACACAAAGGACA
[SEQ ID NO:57]

5' GATGCAAGGTCGCATATGAGACGAGCAATTAAGCGAST [SEQ ID
NO:60]

10 5' AATTCTAATACGACTCACTATAGGGAGAAGGGCACACCACGGACACACA
[SEQ ID NO:58]

5' GATGCAAGGTCGCATATGAGCCGACGAGCCGAACCACA [SEQ ID
NO:61]

15 13. An oligonucleotide primer cocktail for use
in the detection of human papilloma virus type 16,
type 31, type 35 or a combination thereof in a test
sample, the primer cocktail comprising a combination
of oligonucleotide molecules having the following
sequences:

20

5' CCRYTGTGTCCGWWGAA [SEQ ID NO:4]

5' TGCRTGGAGAWAYAMCTA [SEQ ID NO:5]

5' TATRTKTTAGATTTGSAACC [SEQ ID NO:6]

5' X₁-AGRTCAGTTGYCTCDGGT [SEQ ID NO:1]

25 5' X₁-TCYGGTTYTGCTTGTCCA [SEQ ID NO:2]

5' X₁-TGTGTGCTYTGTACRCACAR [SEQ ID NO:3]

wherein X₁ represents a nucleotide sequence comprising
a promoter,

30 14. An oligonucleotide primer cocktail as
claimed in claim 13 wherein X₁ represents a nucleotide
sequence comprising a T7 promoter.

35 15. An oligonucleotide primer cocktail as
claimed in claim 14 wherein X₁ represents a nucleotide
sequence comprising the following sequence:

5'AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62]

- 43 -

16. An oligonucleotide primer cocktail as claimed in claim 13 which comprises the following combination of oligonucleotide molecules:

- 5 5' AATTCTAATACGACTCACTATAGGGAGAAGGAGRTCAGTTGYCTCDGGT
 [SEQ ID NO:42]
 5' GATGCAAGGTCGCATATGAGCCRYTGTGTCCWGWGAA [SEQ ID
 NO:45]
 5' AATTCTAATACGACTCACTATAGGGAGAAGGTCYGGTTYTGCTTGTCCA
10 [SEQ ID NO:43]
 5' GATGCAAGGTCGCATATGAGTGCRTGGAGAWAYAMCTA [SEQ ID
 NO:46]
 5' AATTCTAATACGACTCACTATAGGGAGAAGGTGTGTGCTYTGACRCACAR
 [SEQ ID NO:44]
15 5' GATGCAAGGTCGCATATGAGTATRTKTTAGATTTGSAACC [SEQ ID
 NO:47]

17. A primer cocktail/probe mixture for use in the detection of human papilloma virus type 16, type
20 31, type 35 or a combination thereof in a test sample comprising an oligonucleotide primer cocktail as claimed in any one of claims 13 to 16 and oligonucleotide probe molecules having the following sequences:

- 25 5' TGTAAWCATGCRTGGAGAWA [SEQ ID NO:7]
 5' GAAACCSARSTGTAAWCATG [SEQ ID NO:8]
 5' CATGCRTGGAGAWAYAMCTA [SEQ ID NO:9]
 5' GACAGCTCAGAKGAGGAGGA [SEQ ID NO:10]
30 5' CAACTGAYCTMYACTGTTATGA [SEQ ID NO:11]
 5' CAACTGAYCTMYACTGTTATGAGCAATT [SEQ ID NO:12]

18. A primer cocktail/probe mixture for use in the detection of human papilloma virus type 16, type
35 31, type 35 or a combination thereof in a test sample comprising an oligonucleotide primer cocktail as comprising an oligonucleotide primer cocktail as

- 44 -

claimed in any one of claims 13 to 16 and oligonucleotide probe molecules having the following structures:

5 5' X₂-CCGAGCACTGAYCTMYACTGTTATGAGCTCGG-X₃ [SEQ ID NO:13]

5' X₂-CCAAGCACTGAYCTMYACTGTTATGAGCTTGG-X₃ [SEQ ID NO:14]

10 5' X₂-CCAAGCCAACTGAYCTMYACTGTTATGAGCAGCTTGG-X₃ [SEQ ID NO:15]

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

15

19. An oligonucleotide primer cocktail for use in detecting the presence of human papilloma virus type 52, type 58, type 67 or a combination thereof in a test sample, the primer cocktail comprising a
20 combination of oligonucleotide molecules having the following sequences:

5' TGGACAGGRCGSTGTKCA [SEQ ID NO:18]

5' TGTKCAGWGTGTTGGAGA [SEQ ID NO:19]

25 5' X₁-TCCTCRTCTGAGCTGTCA [SEQ ID NO:16]

5' X₁-TGCTTGTCCATCTGGCCGGT [SEQ ID NO:17]

wherein X₁ represents a nucleotide sequence comprising a promoter,

30

20. An oligonucleotide primer cocktail as claimed in claim 19 wherein X₁ represents a nucleotide sequence comprising a T7 promoter.

35

21. An oligonucleotide primer cocktail as claimed in claim 19 wherein X₁ represents a nucleotide sequence comprising the following sequence:

- 45 -

5' AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62]

22. An oligonucleotide primer cocktail as claimed in claim 19 which comprises the following combination of oligonucleotide molecules:

5' AATTCTAATACGACTCACTATAGGGAGAAGGTCCTCRTCCTGAGCTGTCA
[SEQ ID NO:48]

5' GATGCAAGGTCGCATATGAGTGGACAGGRCGSTGTKCA [SEQ ID
NO:50]

5' AATTCTAATACGACTCACTATAGGGAGAAGGTGCTTGTCATCTGGCCGGT
[SEQ ID NO:49]

5' GATGCAAGGTCGCATATGAGTGTKCAGWGTGTTGGAGA [SEQ ID
NO:51]

15

23. A primer cocktail/probe mixture for use in detecting the presence of human papilloma virus type 52, type 58, type 67 or a combination thereof in a test sample comprising an oligonucleotide primer cocktail as claimed in any one of claims 19 to 22 and oligonucleotide probe molecules having the following sequences:

5' CAACTGACCTAYWCTGCTATGA [SEQ ID NO:20]

5' GAAMCAACTGACCTAYWCTGCTAT [SEQ ID NO:21]

24. A primer cocktail/probe mixture for use in detecting the presence of human papilloma virus type 52, type 58, type 67 or a combination thereof in a test sample comprising an oligonucleotide primer cocktail as claimed in any one of claims 19 to 22 and oligonucleotide probe molecules having the following structures:

5' X₂-CCAAGCAANCAACTGACCTAYWCTGCTAGCTTGG-X₃ [SEQ ID
NO:22]

5' X₂-CCAAGCACTGACCTAYWCTGCTATGAGCTTGG-X₃ [SEQ ID

NO:23]

wherein X_2 and X_3 represent a fluorescent moiety and a quencher moiety capable of substantially or completely
5 quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

25. An oligonucleotide primer cocktail for use in detecting the presence of human papilloma virus
10 type 33, type 58 or a combination thereof in a test sample, the primer cocktail comprising a combination of oligonucleotide molecules having the following sequences:

15 5' CAACTGACCTATWCTGCTA [SEQ ID NO:26]

5' ATCCTGAACCAACTGACCTA [SEQ ID NO:27]

5' X_1 -CAAGTGTRACAACARGTTA [SEQ ID NO:24]

5' X_1 -GCACAGSTAGGGCACACAA [SEQ ID NO:25]

wherein X_1 represents a nucleotide sequence comprising
20 a promoter,

26. An oligonucleotide primer cocktail as claimed in claim 25 wherein X_1 represents a nucleotide
25 sequence comprising a T7 promoter.

27. An oligonucleotide primer cocktail as claimed in claim 26 wherein X_1 represents a nucleotide
sequence comprising the following sequence:

30 5'AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

28. An oligonucleotide primer cocktail as claimed in claim 25 which comprises the following
combination of oligonucleotide molecules:

35 5' AATTCTAATACGACTCACTATAGGGAGAAGGCAAGTGTRACAACARGTTA
[SEQ ID NO:52]

5' GATGCAAGGTCGCATATGAGCAACTGACCTATWCTGCTA [SEQ ID

- 47 -

NO:54]

5' AATTCTAATACGACTCACTATAGGGAGAAGGGCACAGSTAGGGCACACAA
[SEQ ID NO:53]

5' GATGCAAGGTCGCATATGAGATCCTGAACCAACTGACCTA [SEQ ID
5 NO:55]

29. A primer cocktail/probe mixture for use in
detecting the presence of human papilloma virus type
33, type 58 or a combination thereof in a test sample
10 comprising an oligonucleotide primer cocktail as
claimed in any one of claims 25 to 28 and
oligonucleotide probe molecules having the following
sequences:

15 5' GTGACAGCTCAGAYGAGGATGA [SEQ ID NO:28]
5' GGCCAGATGGACAAGCACAAC [SEQ ID NO:29]

30. A primer cocktail/probe mixture for use in
detecting the presence of human papilloma virus type
20 33, type 58 or a combination thereof in a test sample
comprising an oligonucleotide primer cocktail as
claimed in any one of claims 25 to 28 and
oligonucleotide probe molecules having the following
structures:

25 5' X₂-CCAAGCGCCAGATGGACAAGCACAAGCTTGG-X₃ [SEQ ID NO:30]
5' X₂-CCGAGCGCCAGATGGACAAGCACAAGCTCGG-X₃ [SEQ ID
NO:31]

30 wherein X₂ and X₃ represent a fluorescent moiety and a
quencher moiety capable of substantially or completely
quenching the fluorescence from the fluorescent moiety
when the two are held together in close proximity.

35 31. An oligonucleotide a primer cocktail for use
in detecting the presence of human papilloma virus
type 18, type 45 or a combination thereof in a test

- 48 -

sample, the primer cocktail comprising a combination of oligonucleotide molecules having the following sequences:

- 5 5' ACGAGCAATTAAGCGAST [SEQ ID NO:35]
5' CCGACGAGCCGAACCACA [SEQ ID NO:36]
5' X₁-AGCTCAATTCTGSKTCA [SEQ ID NO:32]
5' X₁-ACGGACACACAAAGGACA [SEQ ID NO:33]
5' X₁-GCACACCACGGACACACA [SEQ ID NO:34]
10 wherein X₁ represents a nucleotide sequence comprising a promoter,

32. An oligonucleotide primer cocktail as claimed in claim 31 wherein X₁ represents a nucleotide
15 sequence comprising a T7 promoter.

33. An oligonucleotide primer cocktail as claimed in claim 32 wherein X₁ represents a nucleotide sequence comprising the following sequence:
20 5'AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

34. An oligonucleotide a primer cocktail as claimed in claim 31 which comprises the following combination of oligonucleotide molecules:
25 5' AATTCTAATACGACTCACTATAGGGAGAAGGAGCTCAATTCTGSKTCA [SEQ ID NO:56]
5' GATGCAAGGTCGCATATGAGACGAGCAATTAAGCGAST [SEQ ID NO:59]
30 5' AATTCTAATACGACTCACTATAGGGAGAAGGACGGACACACAAAGGACA [SEQ ID NO:57]
5' GATGCAAGGTCGCATATGAGACGAGCAATTAAGCGAST [SEQ ID NO:60]
5' AATTCTAATACGACTCACTATAGGGAGAAGGGCACACCACGGACACACA [SEQ ID NO:58]
35 5' GATGCAAGGTCGCATATGAGCCGACGAGCCGAACCACA [SEQ ID NO:61]

- 49 -

35. A primer cocktail/probe mixture for use in detecting the presence of human papilloma virus type 18, type 45 or a combination thereof in a test sample comprising an oligonucleotide primer cocktail as
5 claimed in any one of claims 31 to 34 and oligonucleotide probe molecules having the following sequences:

5' AGCCCGACGAGCCGAACCACA [SEQ ID NO:37]
10 5' GTTGTAAGTGTGAMGSCAGAATT [SEQ ID NO:38]

36. A primer cocktail/probe mixture for use in detecting the presence of human papilloma virus type 18, type 45 or a combination thereof in a test sample
15 comprising an oligonucleotide primer cocktail as claimed in any one of claims 31 to 34 and an oligonucleotide probe molecules having the structure:

5' X₂-CCAAGCAGCCCGACGAGCCGAACCACAGCTTGG-X₃ [SEQ ID
20 NO:39]

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety
25 when the two are held together in close proximity.

37. An oligonucleotide primer set for use in the detection of HPV type 16, type 31, type 35 or a combination thereof in a test sample, comprising a
30 first oligonucleotide primer comprising the sequence 5' X₁-AGRTCAGTTGYCTCDGGT [SEQ ID NO:1], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' CCRYTGTGTCCWGWGAA [SEQ ID
35 NO:4].

38. An oligonucleotide primer set for use in the

- 50 -

detection of HPV type 16, type 31, type 35 or a combination thereof in a test sample comprising a first oligonucleotide primer comprising the sequence 5' X₁-TCYGGTTYTGCTTGTTCCA [SEQ ID NO:2], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' TGCRTGGAGAWAYAMCTA [SEQ ID NO:5].

39. An oligonucleotide primer set for use in the detection of HPV type 16, type 31, type 35 or a combination thereof in a test sample comprising a first oligonucleotide primer comprising the sequence 5' X₁-TGTGTGCTYTGTACRCACAR [SEQ ID NO:3], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' TATRTKTTAGATTGSAACC [SEQ ID NO:6].

40. An oligonucleotide primer set according to any one of claims 37 to 39 wherein X₁ represents a nucleotide sequence comprising a T7 promoter.

41. An oligonucleotide primer set according to claim 40 wherein X₁ represents the nucleotide sequence AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

42. A probe/primer mixture for use in the detection of HPV type 16, type 31, type 35 or a combination thereof in a test sample, the mixture comprising an oligonucleotide primer set according to claim 33 and at least one oligonucleotide probe comprising a nucleotide sequence selected from the group consisting of:

5' TGTAAWCATGCRTGGAGAWA [SEQ ID NO:7]

5' GAAACCSARSTGTAAWCATG [SEQ ID NO:8]

- 51 -

5' CATGCRTGGAGAWAYAMCTA [SEQ ID NO:9]

43. A probe/primer mixture for use in the detection of HPV type 16, type 31, type 35 or a combination thereof in a test sample, the mixture comprising an oligonucleotide primer set according to claim 38 or claim 39 and at least one oligonucleotide probe selected from the group consisting of:

oligonucleotide probes comprising one of the following nucleotide sequences:

5' GACAGCTCAGAKGAGGAGGA [SEQ ID NO:10]

5' CAACTGAYCTMYACTGTTATGA [SEQ ID NO:11]

5' CAACTGAYCTMYACTGTTATGAGCAATT [SEQ ID NO:12]

and oligonucleotide probes having one of the following structures:

5' X₂-CCGAGCACTGAYCTMYACTGTTATGAGCTCGG-X₃ [SEQ ID NO:13]

5' X₂-CCAAGCACTGAYCTMYACTGTTATGAGCTTGG-X₃ [SEQ ID NO:14]

5' X₂-CCAAGCCAACTGAYCTMYACTGTTATGAGCAGCTTGG-X₃ [SEQ ID NO:15]

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

44. An oligonucleotide primer set for use in the detection of HPV type 52, type 58 or type 67 or a combination thereof in a test sample comprising a first oligonucleotide primer comprising the sequence 5' X₁-TCCTCRTCCTGAGCTGTCA [SEQ ID NO:16], wherein X₁ represents a nucleotide sequence comprising a

- 52 -

promoter, and a second oligonucleotide primer comprising the sequence 5' TGGACAGGRCGSTGTKCA [SEQ ID NO:18].

5 45. An oligonucleotide primer set for use in the detection of HPV type 52, type 58, type 67 or a combination thereof in a test sample comprising a first oligonucleotide primer comprising the sequence 5' X₁-TGCTTGTCATCTGGCCGGT [SEQ ID NO:17], wherein X₁
10 represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' TGTKCAGWGTGTTGGAGA [SEQ ID NO:19].

15 46. An oligonucleotide primer set according to claim 44 or claim 45 wherein X₁ represents a nucleotide sequence comprising a T7 promoter.

20 47. An oligonucleotide primer set according to claim 46 wherein X₁ represents the nucleotide sequence AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

25 48. A probe/primer mixture for use in the detection of HPV type 52, type 58, type 67 or a combination thereof in a test sample, the mixture comprising an oligonucleotide primer set according to claim 44 or claim 45 and at least one oligonucleotide probe selected from the group consisting of:
30 oligonucleotide probes comprising one of the following nucleotide sequences:

5' CAACTGACCTAYWCTGCTATGA [SEQ ID NO:20]

5' GAAMCAACTGACCTAYWCTGCTAT [SEQ ID NO:21]

35

and oligonucleotide probes having one of the following structures:

- 53 -

5' X₂-CCAAGCAANCAACTGACCTAYWCTGCTAGCTTGG-X₃ [SEQ ID NO:22]

5' X₂-CCAAGCACTGACCTAYWCTGCTATGAGCTTGG-X₃ [SEQ ID NO:23]

5

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

10

49. An oligonucleotide primer set for use in the detection of HPV type 33, type 58 or a combination thereof in a test sample comprising a first oligonucleotide primer comprising the sequence

15 5' X₁-CAAGTGTRACAACARGTTA [SEQ ID NO:24], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' CAACTGACCTATWCTGCTA [SEQ ID NO:26].

20

50. An oligonucleotide primer set for use in the detection of HPV type 33, type 58 or a combination thereof in a test sample comprising a first oligonucleotide primer comprising the sequence

25 5' X₁-GCACAGSTAGGGCACACAA [SEQ ID NO:25], wherein X₁ represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' ATCCTGAACCAACTGACCTA [SEQ ID NO:27].

30

51. An oligonucleotide primer set according to claim 49 or claim 50 wherein X₁ represents a nucleotide sequence comprising a T7 promoter.

35

52. An oligonucleotide primer set according to claim 51 wherein X₁ represents the nucleotide sequence AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].

- 54 -

53. A probe/primer mixture for use in the detection of HPV type 33, type 58 or a combination thereof in a test sample, the mixture comprising an oligonucleotide primer set according to claim 49 or
5 claim 50 and at least one oligonucleotide probe selected from the group consisting of:

oligonucleotide probes comprising one of the following nucleotide sequences:

10

5' GTGACAGCTCAGAYGAGGATGA [SEQ ID NO:28]

5' GGCCAGATGGACAAGCACAAC [SEQ ID NO:29]

15

and oligonucleotide probes having one of the following structures:

5' X₂-CCAAGCGCCAGATGGACAAGCACAAGCTTGG-X₃ [SEQ ID NO:30]

5' X₂-CCGAGCGCCAGATGGACAAGCACAAGCTCGG-X₃ [SEQ ID NO:31]

20

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

25

54. An oligonucleotide primer set for use in the detection of HPV type 45, type 18 or a combination thereof in a test sample comprising a first oligonucleotide primer comprising the sequence
5' X₁-AGCTCAATTCTGSCKTCA [SEQ ID NO:32], wherein X₁
30 represents a nucleotide sequence comprising a promoter, and a second oligonucleotide primer comprising the sequence 5' ACGAGCAATTAAGCGAST [SEQ ID NO:35].

35

55. An oligonucleotide primer set for use in the detection of HPV type 45, type 18 or a combination thereof in a test sample comprising a first

- 55 -

oligonucleotide primer comprising the sequence
5' X₁-ACGGACACACAAAGGACA [SEQ ID NO:33], wherein X₁
represents a nucleotide sequence comprising a
promoter, and a second oligonucleotide primer
5 comprising the sequence 5' ACGAGCAATTAAGCGAST [SEQ ID
NO:35].

56. An oligonucleotide primer set for use in the
detection of HPV type 45, type 18 or a combination
10 thereof in a test sample comprising a first
oligonucleotide primer comprising the sequence
5' X₁-GCACACCACGGACACACA [SEQ ID NO:34], wherein X₁
represents a nucleotide sequence comprising a
promoter, and a second oligonucleotide primer
15 comprising the sequence 5' CCGACGAGCCGAACCACA [SEQ ID
NO:36].

57. An oligonucleotide primer set according to
any one of claims 54 to 56 wherein X₁ represents a
20 nucleotide sequence comprising a T7 promoter.

58. An oligonucleotide primer set according to
claim 57 wherein X₁ represents the nucleotide sequence
AATTCTAATACGACTCACTATAGGGAGAAGG [SEQ ID NO:62].
25

59. A probe/primer mixture for use in the
detection of HPV type 45, type 18 or a combination
thereof in a test sample, the mixture comprising an
oligonucleotide primer set according to claim 54 and
30 at least one of: an oligonucleotide probe comprising
the nucleotide sequence 5' AGCCCGACGAGCCGAACCACA [37]
or an oligonucleotide probe having the structure
5' X₂-CCAAGCAGCCCGACGAGCCGAACCACAGCTTGG-X₃ [SEQ ID
NO:39] wherein X₂ and X₃ represent a fluorescent moiety.
35 and a quencher moiety capable of substantially or
completely quenching the fluorescence from the
fluorescent moiety when the two are held together in

close proximity.

60. A probe/primer mixture for use in the detection of HPV type 45, type 18 or a combination thereof in a test sample, the mixture comprising an oligonucleotide primer set according to claim 55 or claim 56 and at least one of: an oligonucleotide probe comprising the nucleotide sequence
5' GTTGTAAGTGTGAMGSCAGAATT [SEQ ID NO:38] or an oligonucleotide probe having the structure
5' X₂-CCAAGCAGCCCGACGAGCCGAACACAGCTTGG-X₃ [SEQ ID NO:39] wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity.

61. A method of detecting HPV type 16, type 31, type 35 or a combination thereof in a test sample, the method comprising:

(a) assembling a reaction mixture comprising a primer cocktail as defined in any one of claims 13 to 16, an RNA directed DNA polymerase, a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without hydrolysing single or double stranded RNA or DNA, an RNA polymerase that recognises said promoter, and ribonucleoside and deoxyribonucleoside triphosphates;

(b) incubating said reaction medium with a preparation of nucleic acid isolated from a test sample suspected of containing HPV under reaction conditions which permit a NASBA amplification reaction; and

(c) detecting and/or quantitatively measuring any HPV-specific product of the NASBA amplification reaction.

- 57 -

62. A method as claimed in claim 61 which comprises the further step of capturing the NASBA reaction product by hybridisation to a mixture of probe oligonucleotides attached to a solid support, wherein the mixture of probe oligonucleotides comprises oligonucleotides having the following sequences:

5' TGTAAWCATGCRTGGAGAWA [SEQ ID NO:7]
5' GAAACCSARSTGTAAWCATG [SEQ ID NO:8]
10 5' CATGCRTGGAGAWAYAMCTA [SEQ ID NO:9]
5' GACAGCTCAGAKGAGGAGGA [SEQ ID NO:10]
5' CAACTGAYCTMYACTGTTATGA [SEQ ID NO:11]
5' CAACTGAYCTMYACTGTTATGAGCAATT [SEQ ID NO:12]

63. A method as claimed in claim 61 wherein the reaction mixture further comprises probe oligonucleotides having the following structures:

5' X₂-CCGAGCACTGAYCTMYACTGTTATGAGCTCGG-X₃ [SEQ ID
20 NO:13]
5' X₂-CCAAGCACTGAYCTMYACTGTTATGAGCTTGG-X₃ [SEQ ID
NO:14]
5' X₂-CCAAGCCAAGCTGAYCTMYACTGTTATGAGCAGCTTGG-X₃ [SEQ ID
NO:15]

25 wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity and the formation of any HPV-specific NASBA product in the NASBA reaction is monitored by detecting fluorescence from the fluorescent moiety.

64. A method of detecting HPV type 52, type 58, type 67 or a combination thereof in a test sample, the method comprising:

- 58 -

(a) assembling a reaction mixture comprising a primer cocktail as defined in any one of claims 19 to 22, an RNA directed DNA polymerase, a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without hydrolysing single or double stranded RNA or DNA, an RNA polymerase that recognises said promoter, and ribonucleoside and deoxyribonucleoside triphosphates;

(b) incubating said reaction medium with a preparation of nucleic acid isolated from a test sample suspected of containing HPV under reaction conditions which permit a NASBA amplification reaction; and

(c) detecting and/or quantitatively measuring any HPV-specific product of the NASBA amplification reaction.

65. A method as claimed in claim 64 which comprises the further step of capturing the NASBA reaction product by hybridisation to a mixture of probe oligonucleotides attached to a solid support, wherein the mixture of probe oligonucleotides comprises oligonucleotides having the following sequences:

5' CAACTGACCTAYWCTGCTATGA [SEQ ID NO:20]
5' GAAMCAACTGACCTAYWCTGCTAT [SEQ ID NO:21]

66. A method as claimed in claim 64 wherein wherein the reaction mixture further comprises probe oligonucleotides having the following structures:

5' X₂-CCAAGCAANCAACTGACCTAYWCTGCTAGCTTGG-X₃ [SEQ ID NO:22]
5' X₂-CCAAGCACTGACCTAYWCTGCTATGAGCTTGG-X₃ [SEQ ID NO:23]

wherein X₂ and X₃ represent a fluorescent moiety and a

- 59 -

quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity and the formation of any HPV-specific NASBA product in the NASBA reaction is monitored by detecting fluorescence from the fluorescent moiety.

67. A method of detecting HPV type 33, type 58 or a combination thereof in a test sample, the method comprising:

(a) assembling a reaction mixture comprising a primer cocktail as defined in any one of claims 25 to 28, an RNA directed DNA polymerase, a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without hydrolysing single or double stranded RNA or DNA, an RNA polymerase that recognises said promoter, and ribonucleoside and deoxyribonucleoside triphosphates;

(b) incubating said reaction medium with a preparation of nucleic acid isolated from a test sample suspected of containing HPV under reaction conditions which permit a NASBA amplification reaction; and

(c) detecting and/or quantitatively measuring any HPV-specific product of the NASBA amplification reaction.

68. A method as claimed in claim 67 which comprises the further step of capturing the NASBA reaction product by hybridisation to a mixture of probe oligonucleotides attached to a solid support, wherein the mixture of probe oligonucleotides comprises oligonucleotides having the following sequences:

5' GTGACAGCTCAGAYGAGGATGA [SEQ ID NO:28]

5' GGCCAGATGGACAAGCACAAC [SEQ ID NO:29]

- 60 -

69. A method as claimed in claim 67 wherein the reaction mixture further comprises probe oligonucleotides having the following structures:

- 5 5' X₂-CCAAGCGCCAGATGGACAAGCACAAGCTTGG-X₃ [SEQ ID NO:30]
 5' X₂-CCGAGCGCCAGATGGACAAGCACAAGCTCGG-X₃ [SEQ ID NO:31]

 wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely
10 quenching the fluorescence from the fluorescent moiety when the two are held together in close proximity and the formation of any HPV-specific NASBA product in the NASBA reaction is monitored by detecting
 fluorescence from the fluorescent moiety.

15

 70. A method of detecting HPV type 18, type 45 or a combination thereof in a test sample, the method comprising:

- 20 (a) assembling a reaction mixture comprising a primer cocktail as defined in any one of claims 31 to 34, an RNA directed DNA polymerase, a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without hydrolysing single or double stranded RNA or
25 DNA, an RNA polymerase that recognises said promoter, and ribonucleoside and deoxyribonucleoside triphosphates;

- (b) incubating said reaction medium with a preparation of nucleic acid isolated from a test
30 sample suspected of containing HPV under reaction conditions which permit a NASBA amplification reaction; and

- (c) detecting and/or quantitatively measuring any HPV-specific product of the NASBA amplification
35 reaction.

71. A method as claimed in claim 70 which

- 61 -

comprises the further step of capturing the NASBA reaction product by hybridisation to a mixture of probe oligonucleotides attached to a solid support, wherein the mixture of probe oligonucleotides comprises
5 oligonucleotides having the following sequences:

5' AGCCCGACGAGCCGAACCACA [SEQ ID NO:37]

5' GTTGTAAGTGTGAMGSCAGAATT [SEQ ID NO:38]

10 72. A method as claimed in claim 71 wherein the reaction mixture further comprises a probe oligonucleotide having the following sequence:

15 5' X₂-CCAAGCAGCCCGACGAGCCGAACCACAGCTTGG-X₃ [SEQ ID NO:39]

wherein X₂ and X₃ represent a fluorescent moiety and a quencher moiety capable of substantially or completely quenching the fluorescence from the fluorescent moiety
20 when the two are held together in close proximity and the formation of any HPV-specific NASBA product in the NASBA reaction is monitored by detecting fluorescence from the fluorescent moiety.

25 73. A reagent kit for use in the detection of HPV type 16, type 31, type 35 or a combination thereof by NASBA, the kit comprising an oligonucleotide primer cocktail as defined in any one of claims 13 to 16 and optionally an enzyme mixture comprising an RNA
30 directed DNA polymerase, a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without hydrolysing single or double stranded RNA or DNA, an RNA polymerase that recognises said promoter.

35 74. A reagent kit for use in the detection of HPV type 52, type 58, type 67 or a combination thereof by NASBA, the kit comprising an oligonucleotide primer

- 62 -

cocktail as defined in any one of claims 19 to 22 and optionally an enzyme mixture comprising an RNA directed DNA polymerase, a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without
5 hydrolysing single or double stranded RNA or DNA, an RNA polymerase that recognises said promoter.

75. A reagent kit for use in the detection of HPV type 33, type 58 or a combination thereof by
10 NASBA, the kit comprising an oligonucleotide primer cocktail as defined in any one of claims 25 to 38 and optionally an enzyme mixture comprising an RNA directed DNA polymerase, a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without
15 hydrolysing single or double stranded RNA or DNA, an RNA polymerase that recognises said promoter.

76. A reagent kit for use in the detection of HPV type 18, type 45 or a combination thereof by
20 NASBA, the kit comprising an oligonucleotide primer cocktail as defined in any one of claims 31 to 34 and optionally an enzyme mixture comprising an RNA directed DNA polymerase, a ribonuclease that hydrolyses the RNA strand of an RNA-DNA hybrid without
25 hydrolysing single or double stranded RNA or DNA, an RNA polymerase that recognises said promoter.

SEQUENCE LISTING

<110> NORCHIP A/S

<120> METHODS FOR DETECTION OF HUMAN PAPILLOMAVIRUS mRNA

<130> SJA/55661/001

<140>

<141>

<160> 62

<170> PatentIn Ver. 2.0

<210> 1

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 1

agrtcagttg yctcdggt

18

<210> 2

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 2

tcyggttytg cttgtcca

18

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 3

tgtgtgctyt gtacrcacar

20

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
Oligonucleotide

<400> 4
ccrytgtgtc cwggwgaa 18

<210> 5
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 5
tgcrtggaga wayamcta 18

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 6
tatrtkttag atttgsaacc 20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 7
tgtaawcatg crtggagawa 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 8
gaaaccsars tgtaawcatg 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 9
catgcrtgga gawayamcta 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 10
gacagctcag akaggagga 20

<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 11
caactgayct myactgttat ga 22

<210> 12
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 12
caactgayct myactgttat gagcaatt 28

<210> 13
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 13
ccgagcactg ayctmyactg ttatgagctc gg 32

<210> 14
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 14
ccaagcactg ayctmyactg ttatgagctt gg 32

<210> 15
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 15
ccaagccaac tgayctmyac tgttatgagc agcttgg 37

<210> 16
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 16
tcctcrtctg agctgtca 18

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 17
tgcttgcca tctggccggt 20

<210> 18
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 18
tggacaggrc gstgtkca 18

<210> 19
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 19
tgtkcagwgt gttggaga 18

<210> 20
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 20
caactgacct aywctgctat ga 22

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 21
gaamcaactg acctaywctg ctat 24

<210> 22
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 22
ccaagcaanc aactgaccta ywctgctagc ttgg 34

<210> 23
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 23
ccaagcactg acctaywctg ctatgagctt gg 32

<210> 24
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 24
caagtgtrac aacargtta 19

<210> 25
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 25
gcacagstag ggcacacaa 19

<210> 26
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 26
caactgacct atwctgcta 19

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 27
atcctgaacc aactgaccta 20

<210> 28
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 28
gtgacagctc agaygaggat ga 22

<210> 29
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 34
gcacaccacg gacacaca 18

<210> 35
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 35
acgagcaatt aagcgast 18

<210> 36
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 36
ccgacgagcc gaaccaca 18

<210> 37
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 37
agcccgacga gccgaaccac a 21

<210> 38
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 38
gttgtaagtg tgamgscaga att 23

<210> 39
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 39
ccaagcagcc cgacgagccg aaccacagct tgg 33

<210> 40
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 40
aattctaata cgactcacta taggg 25

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 41
gatgcaaggt cgcatatgag 20

<210> 42
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 42
aattctaata cgactcacta tagggagaag gagrtcagtt gyctcdggt 49

<210> 43
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 43
aattctaata cgactcacta tagggagaag gtcyggttyt gcttgcca 49

<210> 44
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 44
aattctaata cgactcacta tagggagaag gtgtgtgcty tgtacrcaca r 51

<210> 45
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 45
gatgcaaggt cgcatatgag ccrytgtgtc cwgwwgaa 38

<210> 46
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 46
gatgcaaggt cgcatatgag tgcrtggaga wayamcta 38

<210> 47
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 47
gatgcaaggt cgcatatgag tatrtkttag atttgsaacc 40

<210> 48
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 48
aattctaata cgactcacta tagggagaag gtctctrtct gagctgtca 49

<210> 49
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 49
aattctaata cgactcacta tagggagaag gtgcttgtcc aatctggccg gt 52

<210> 50
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 50
gatgcaaggt cgcatatgag tggacaggrc gstgtkca 38

<210> 51
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 51
gatgcaaggt cgcatatgag tgtkcagwgt gttggaga 38

<210> 52
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 52
aattctaata cgactcacta tagggagaag gcaagtgtra caacargtta 50

<210> 53
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 53
aattctaata cgactcacta tagggagaag ggcacagsta gggcacacaa 50

<210> 54
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 54
gatgcaaggt cgcatatgag caactgacct atwctgcta 39

<210> 55
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 55
gatgcaaggt cgcatatgag atcctgaacc aactgaccta 40

<210> 56
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 56
aattctaata cgactcacta tagggagaag gagctcaatt ctgscktca 49

<210> 57
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 57
aattctaata cgactcacta tagggagaag gacggacaca.caaaggaca 49

<210> 58
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 58
aattctaata cgactcacta tagggagaag ggcacaccac ggacacaca 49

<210> 59
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 59
gatgcaaggt cgcatatgag acgagcaatt aagcgast 38

<210> 60
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 60
gatgcaaggt cgcatatgag acgagcaatt aagcgast 38

<210> 61
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 61
gatgcaaggt cgcatatgag ccgacgagcc gaaccaca 38

<210> 62
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide

<400> 62
aattctaata cgactcacta tagggagaag g 31

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/008460 A3

(51) International Patent Classification⁷: C12Q 1/70

(21) International Application Number: PCT/GB01/03293

(22) International Filing Date: 20 July 2001 (20.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0018050.5 21 July 2000 (21.07.2000) GB

(71) Applicant (*for all designated States except US*):
NORCHIP A/S [NO/NO]; Industriveien 8, N-3490
Klokkarstua (NO).

(71) Applicant (*for MG only*): ALLARD, Susan, Joyce
[GB/GB]; Verulam Gardens, 70 Gray's Inn Road, London
WC1X 8BT (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): KARLSEN, Frank
[NO/NO]; Hovkastet 2, N-3490 Klokkarstua (NO).

(74) Agent: BOULT WADE TENNANT; Verulam Gardens,
70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designation US*
- *of inventorship (Rule 4.17(iv)) for US only*

Published:

- *with international search report*

(88) Date of publication of the international search report:
9 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/008460 A3

(54) Title: METHODS FOR DETECTION OF HUMAN PAPILLOMAVIRUS MRNA

(57) Abstract: Methods for detecting the presence of mRNA transcripts from the E6 or E7 genes of human papillomavirus in clinical samples using nucleic acid sequence-based amplification. Sets of degenerate oligonucleotide primers which may be used for simultaneous detection of multiple HPV types are also described.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/03293

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, BIOSIS, MEDLINE, SEQUENCE SEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 506 105 A (HAYDOCK PAUL V) 9 April 1996 (1996-04-09) SEQ ID 2	1
X	--- US 5 695 926 A (CROS PHILIPPE ET AL) 9 December 1997 (1997-12-09) SEQ ID 40 example 14	1,13-18, 37-43, 61-63,73
X	--- US 5 618 536 A (LOWY DOUGLAS R ET AL) 8 April 1997 (1997-04-08) SEQ ID 5,6	1
A	--- US 5 580 970 A (HENDRICKS DAVID A ET AL) 3 December 1996 (1996-12-03) SEQ ID 7 --- -/-	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 October 2002

Date of mailing of the international search report

05.02.03

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luzzatto, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/03293

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 386 734 A (BEHRINGWERKE AG) 12 September 1990 (1990-09-12) column 3, line 35 - line 40 ---	1
A	WO 95 22626 A (STICHTING RES FONDS PATHOLOGIE ;MEIJER CHRISTOPHORUS JOANNES L (NL) 24 August 1995 (1995-08-24) page 20, line 22 - line 32; tables 1A,1B,2 ---	1
A	EP 0 301 968 A (IRE CELLTARG SA) 1 February 1989 (1989-02-01) the whole document ---	
A	EP 0 477 972 A (ABBOTT LAB) 1 April 1992 (1992-04-01) page 8, line 1 -page 13, line 40; claims 11,12 -----	1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 01/03293

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-3, 13-18, 37-43, 61-63, 73

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-3, 13-18, 37-43, 61-63, 73

Probes and primers for the detection of HPV type 16, 31, 35 or combinations thereof, kits comprising them and a nucleic acid amplification method based on the NASBA procedure for the detection of HPV of type 16, 31 or 35 or combination thereof comprising the use of the said probes/primers.

2. Claims: 4-6, 19-24, 44-48, 64-66, 74

Probes and primers for the detection of HPV type 52, 58, 67 or combinations thereof, kits comprising them and a nucleic acid amplification method based on the NASBA procedure for the detection of HPV of type 52, 58, 67 or combination thereof comprising the use of the said probes/primers.

3. Claims: 7-9, 25-30, 49-53, 67-69, 75

Probes and primers for the detection of HPV type 33, 58 or combinations thereof, kits comprising them and a nucleic acid amplification method based on the NASBA procedure for the detection of HPV of type 33, 58 or combination thereof comprising the use of the said probes/primers.

4. Claims: 10-12, 31-36, 54-60, 70-72, 76

Probes and primers for the detection of HPV type 18, 45 or combinations thereof, kits comprising them and a nucleic acid amplification method based on the NASBA procedure for the detection of HPV of type 18, 45 or combination thereof comprising the use of the said probes/primers.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/03293

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5506105	A	09-04-1996	NONE	
US 5695926	A	09-12-1997	FR 2663040 A1	13-12-1991
			AT 133995 T	15-02-1996
			AU 650885 B2	07-07-1994
			AU 7995391 A	07-01-1992
			CA 2059657 A1	12-12-1991
			DE 69116993 D1	21-03-1996
			DE 69116993 T2	14-11-1996
			DK 486661 T3	17-06-1996
			EP 0486661 A1	27-05-1992
			ES 2084167 T3	01-05-1996
			FI 102296 B1	13-11-1998
			WO 9119812 A1	26-12-1991
			JP 5501957 T	15-04-1993
			JP 3289089 B2	04-06-2002
			PT 97939 A ,B	31-03-1992
US 5618536	A	08-04-1997	US 5437951 A	01-08-1995
			AU 3828495 A	02-05-1996
			AU 717647 B2	30-03-2000
			AU 4447899 A	28-10-1999
			EP 1018555 A2	12-07-2000
			EP 0789766 A1	20-08-1997
			JP 3343912 B2	11-11-2002
			JP 10506796 T	07-07-1998
			JP 2002053597 A	19-02-2002
			WO 9611274 A1	18-04-1996
			US 5855891 A	05-01-1999
			US 2002164350 A1	07-11-2002
			AU 683220 B2	06-11-1997
			AU 4847593 A	29-03-1994
			CA 2143845 A1	17-03-1994
			EP 0662132 A1	12-07-1995
			JP 8504087 T	07-05-1996
			JP 2001333788 A	04-12-2001
			WO 9405792 A1	17-03-1994
			US 5756284 A	26-05-1998
			US 5709996 A	20-01-1998
			US 5871998 A	16-02-1999
			US 5744142 A	28-04-1998
			US 5716620 A	10-02-1998
			US 5985610 A	16-11-1999
US 5580970	A	03-12-1996	AU 6966991 A	26-06-1991
			DE 69022246 D1	12-10-1995
			DE 69022246 T2	29-02-1996
			DE 69033850 D1	13-12-2001
			DE 69033850 T2	06-06-2002
			EP 0502994 A1	16-09-1992
			EP 0662518 A2	12-07-1995
			JP 5501650 T	02-04-1993
			WO 9108312 A1	13-06-1991
EP 0386734	A	12-09-1990	DE 3907721 A1	20-09-1990
			AT 128144 T	15-10-1995
			AU 624485 B2	11-06-1992
			AU 5110490 A	13-09-1990

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/03293

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0386734 A		CA 2011878 A1	10-09-1990
		DE 59009669 D1	26-10-1995
		DK 386734 T3	05-02-1996
		EP 0386734 A2	12-09-1990
		ES 2078255 T3	16-12-1995
		IE 67798 B1	01-05-1996
		JP 2289600 A	29-11-1990
		JP 3056502 B2	26-06-2000
		KR 164215 B1	15-01-1999
		PT 93393 A ,B	07-11-1990
		US 5547846 A	20-08-1996
WO 9522626 A	24-08-1995	AT 222295 T	15-08-2002
		AU 685233 B2	15-01-1998
		AU 1672295 A	04-09-1995
		CA 2183758 A1	24-08-1995
		DE 69527776 D1	19-09-2002
		DK 746627 T3	16-12-2002
		EP 0746627 A1	11-12-1996
		JP 9509062 T	16-09-1997
		WO 9522626 A1	24-08-1995
		US 6352825 B1	05-03-2002
EP 0301968 A	01-02-1989	FR 2618782 A1	03-02-1989
		FR 2629458 A2	06-10-1989
		AT 82021 T	15-11-1992
		DE 3875667 D1	10-12-1992
		DE 3875667 T2	18-03-1993
		EP 0301968 A1	01-02-1989
		ES 2052758 T3	16-07-1994
		GR 3006284 T3	21-06-1993
		JP 2812678 B2	22-10-1998
		JP 10057099 A	03-03-1998
		JP 1128800 A	22-05-1989
EP 0477972 A	01-04-1992	US 4983728 A	08-01-1991
		AT 142276 T	15-09-1996
		AU 650055 B2	09-06-1994
		AU 8482691 A	02-04-1992
		CA 2052413 A1	29-03-1992
		DE 69121821 D1	10-10-1996
		DE 69121821 T2	03-04-1997
		DK 477972 T3	10-02-1997
		EP 0477972 A2	01-04-1992
		ES 2094178 T3	16-01-1997
		GR 3021724 T3	28-02-1997
		JP 4281791 A	07-10-1992
		JP 2001231587 A	28-08-2001
		US 5484699 A	16-01-1996